doc_id,adu1_pos,adu2_pos,adu1_aty,adu2_aty,rel_label,adu1_text,adu2_text
23352440,1,2,Premise,Premise,none,"Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months.","Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78]."
23352440,1,3,Premise,Premise,none,"Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months.","Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months."
23352440,1,4,Premise,Claim,support,"Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months.",This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.
23352440,1,5,Premise,Claim,none,"Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months.","Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits."
23352440,2,1,Premise,Premise,none,"Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78].","Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months."
23352440,2,3,Premise,Premise,none,"Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78].","Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months."
23352440,2,4,Premise,Claim,support,"Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78].",This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.
23352440,2,5,Premise,Claim,none,"Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78].","Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits."
23352440,3,1,Premise,Premise,none,"Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months.","Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months."
23352440,3,2,Premise,Premise,none,"Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months.","Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78]."
23352440,3,4,Premise,Claim,support,"Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months.",This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.
23352440,3,5,Premise,Claim,none,"Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months.","Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits."
23352440,4,1,Claim,Premise,none,This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.,"Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months."
23352440,4,2,Claim,Premise,none,This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.,"Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78]."
23352440,4,3,Claim,Premise,none,This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.,"Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months."
23352440,4,5,Claim,Claim,none,This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.,"Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits."
23352440,5,1,Claim,Premise,none,"Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits.","Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months."
23352440,5,2,Claim,Premise,none,"Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits.","Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78]."
23352440,5,3,Claim,Premise,none,"Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits.","Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months."
23352440,5,4,Claim,Claim,none,"Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits.",This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy.
22857983,1,2,Premise,Premise,none,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD.","No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,1,3,Premise,Premise,none,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD.","bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,1,4,Premise,Premise,none,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD.",Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).
22857983,1,5,Premise,Premise,none,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD.",Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.
22857983,1,6,Premise,Claim,support,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD.",IAD showed benefits in the treatment of advanced PCa with respect to QoL.
22857983,1,7,Premise,Claim,none,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD.",The prevalence of AEs was not significantly lower with IAD.
22857983,2,1,Premise,Premise,none,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;","Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,2,3,Premise,Premise,none,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;","bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,2,4,Premise,Premise,none,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;",Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).
22857983,2,5,Premise,Premise,none,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;",Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.
22857983,2,6,Premise,Claim,none,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;",IAD showed benefits in the treatment of advanced PCa with respect to QoL.
22857983,2,7,Premise,Claim,support,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;",The prevalence of AEs was not significantly lower with IAD.
22857983,3,1,Premise,Premise,none,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively.","Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,3,2,Premise,Premise,none,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively.","No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,3,4,Premise,Premise,none,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively.",Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).
22857983,3,5,Premise,Premise,none,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively.",Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.
22857983,3,6,Premise,Claim,none,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively.",IAD showed benefits in the treatment of advanced PCa with respect to QoL.
22857983,3,7,Premise,Claim,support,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively.",The prevalence of AEs was not significantly lower with IAD.
22857983,4,1,Premise,Premise,none,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,4,2,Premise,Premise,none,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,4,3,Premise,Premise,none,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,4,5,Premise,Premise,none,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.
22857983,4,6,Premise,Claim,none,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).,IAD showed benefits in the treatment of advanced PCa with respect to QoL.
22857983,4,7,Premise,Claim,support,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).,The prevalence of AEs was not significantly lower with IAD.
22857983,5,1,Premise,Premise,none,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,5,2,Premise,Premise,none,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,5,3,Premise,Premise,none,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,5,4,Premise,Premise,none,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).
22857983,5,6,Premise,Claim,none,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.,IAD showed benefits in the treatment of advanced PCa with respect to QoL.
22857983,5,7,Premise,Claim,support,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.,The prevalence of AEs was not significantly lower with IAD.
22857983,6,1,Claim,Premise,none,IAD showed benefits in the treatment of advanced PCa with respect to QoL.,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,6,2,Claim,Premise,none,IAD showed benefits in the treatment of advanced PCa with respect to QoL.,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,6,3,Claim,Premise,none,IAD showed benefits in the treatment of advanced PCa with respect to QoL.,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,6,4,Claim,Premise,none,IAD showed benefits in the treatment of advanced PCa with respect to QoL.,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).
22857983,6,5,Claim,Premise,none,IAD showed benefits in the treatment of advanced PCa with respect to QoL.,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.
22857983,6,7,Claim,Claim,none,IAD showed benefits in the treatment of advanced PCa with respect to QoL.,The prevalence of AEs was not significantly lower with IAD.
22857983,7,1,Claim,Premise,none,The prevalence of AEs was not significantly lower with IAD.,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,7,2,Claim,Premise,none,The prevalence of AEs was not significantly lower with IAD.,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,7,3,Claim,Premise,none,The prevalence of AEs was not significantly lower with IAD.,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,7,4,Claim,Premise,none,The prevalence of AEs was not significantly lower with IAD.,Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44).
22857983,7,5,Claim,Premise,none,The prevalence of AEs was not significantly lower with IAD.,Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm.
22857983,7,6,Claim,Claim,none,The prevalence of AEs was not significantly lower with IAD.,IAD showed benefits in the treatment of advanced PCa with respect to QoL.
24092240,1,2,Premise,Premise,none,"CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01).","There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05)."
24092240,1,3,Premise,Premise,none,"CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01).",there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05).
24092240,1,4,Premise,Claim,support,"CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01).","CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients."
24092240,2,1,Premise,Premise,none,"There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05).","CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01)."
24092240,2,3,Premise,Premise,none,"There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05).",there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05).
24092240,2,4,Premise,Claim,support,"There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05).","CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients."
24092240,3,1,Premise,Premise,none,there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05).,"CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01)."
24092240,3,2,Premise,Premise,none,there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05).,"There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05)."
24092240,3,4,Premise,Claim,support,there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05).,"CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients."
24092240,4,1,Claim,Premise,none,"CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients.","CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01)."
24092240,4,2,Claim,Premise,none,"CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients.","There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05)."
24092240,4,3,Claim,Premise,none,"CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients.",there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05).
9106647,1,2,Premise,Premise,none,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival.",Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.
9106647,1,3,Premise,Premise,none,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival.","Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01)."
9106647,1,4,Premise,Premise,none,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival.","With the exception of acute nausea and vomiting associated with intravenous chemotherapy,"
9106647,1,5,Premise,Premise,none,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival.",all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.
9106647,1,6,Premise,Claim,support,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival.",These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.
9106647,2,1,Premise,Premise,support,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival."
9106647,2,3,Premise,Premise,none,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01)."
9106647,2,4,Premise,Premise,none,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,"
9106647,2,5,Premise,Premise,none,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.
9106647,2,6,Premise,Claim,none,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.
9106647,3,1,Premise,Premise,none,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01).","Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival."
9106647,3,2,Premise,Premise,none,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01).",Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.
9106647,3,4,Premise,Premise,none,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01).","With the exception of acute nausea and vomiting associated with intravenous chemotherapy,"
9106647,3,5,Premise,Premise,none,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01).",all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.
9106647,3,6,Premise,Claim,support,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01).",These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.
9106647,4,1,Premise,Premise,none,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,","Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival."
9106647,4,2,Premise,Premise,none,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,",Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.
9106647,4,3,Premise,Premise,none,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,","Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01)."
9106647,4,5,Premise,Premise,attack,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,",all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.
9106647,4,6,Premise,Claim,none,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,",These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.
9106647,5,1,Premise,Premise,none,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival."
9106647,5,2,Premise,Premise,none,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.
9106647,5,3,Premise,Premise,none,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01)."
9106647,5,4,Premise,Premise,none,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,"
9106647,5,6,Premise,Claim,support,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.
9106647,6,1,Claim,Premise,none,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival."
9106647,6,2,Claim,Premise,none,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.,Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy.
9106647,6,3,Claim,Premise,none,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01)."
9106647,6,4,Claim,Premise,none,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,"
9106647,6,5,Claim,Premise,none,These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.,all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group.
20006921,1,2,Premise,Premise,none,"The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue.","At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively."
20006921,1,3,Premise,Premise,none,"The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue.",A higher proportion of patients in Z-360 groups reported improvement in pain.
20006921,1,4,Premise,Claim,support,"The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue.",Z-360 is safe and well tolerated when combined with gemcitabine.
20006921,2,1,Premise,Premise,none,"At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively.","The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue."
20006921,2,3,Premise,Premise,none,"At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively.",A higher proportion of patients in Z-360 groups reported improvement in pain.
20006921,2,4,Premise,Claim,support,"At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively.",Z-360 is safe and well tolerated when combined with gemcitabine.
20006921,3,1,Premise,Premise,none,A higher proportion of patients in Z-360 groups reported improvement in pain.,"The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue."
20006921,3,2,Premise,Premise,none,A higher proportion of patients in Z-360 groups reported improvement in pain.,"At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively."
20006921,3,4,Premise,Claim,attack,A higher proportion of patients in Z-360 groups reported improvement in pain.,Z-360 is safe and well tolerated when combined with gemcitabine.
20006921,4,1,Claim,Premise,none,Z-360 is safe and well tolerated when combined with gemcitabine.,"The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue."
20006921,4,2,Claim,Premise,none,Z-360 is safe and well tolerated when combined with gemcitabine.,"At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively."
20006921,4,3,Claim,Premise,none,Z-360 is safe and well tolerated when combined with gemcitabine.,A higher proportion of patients in Z-360 groups reported improvement in pain.
20026818,1,2,Premise,Premise,none,Approximately one-half had hematologic toxicities and toxicity-related treatment delays.,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever."
20026818,1,3,Premise,Premise,none,Approximately one-half had hematologic toxicities and toxicity-related treatment delays.,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,"
20026818,1,4,Premise,Premise,none,Approximately one-half had hematologic toxicities and toxicity-related treatment delays.,they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.
20026818,1,5,Premise,Claim,support,Approximately one-half had hematologic toxicities and toxicity-related treatment delays.,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol."
20026818,2,1,Premise,Premise,none,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever.",Approximately one-half had hematologic toxicities and toxicity-related treatment delays.
20026818,2,3,Premise,Premise,none,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever.","Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,"
20026818,2,4,Premise,Premise,none,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever.",they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.
20026818,2,5,Premise,Claim,support,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever.","Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol."
20026818,3,1,Premise,Premise,none,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,",Approximately one-half had hematologic toxicities and toxicity-related treatment delays.
20026818,3,2,Premise,Premise,none,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,","Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever."
20026818,3,4,Premise,Premise,none,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,",they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.
20026818,3,5,Premise,Claim,support,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,","Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol."
20026818,4,1,Premise,Premise,none,they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.,Approximately one-half had hematologic toxicities and toxicity-related treatment delays.
20026818,4,2,Premise,Premise,none,they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever."
20026818,4,3,Premise,Premise,none,they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,"
20026818,4,5,Premise,Claim,support,they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol."
20026818,5,1,Claim,Premise,none,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol.",Approximately one-half had hematologic toxicities and toxicity-related treatment delays.
20026818,5,2,Claim,Premise,none,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol.","Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever."
20026818,5,3,Claim,Premise,none,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol.","Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,"
20026818,5,4,Claim,Premise,none,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol.",they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.
24045440,1,2,Premise,Premise,none,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).,Some patients reported symptoms of fecal incontinence.
24045440,1,3,Premise,Premise,none,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144)."
24045440,1,4,Premise,Claim,support,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).,The outcome of these patients remains unsatisfactory.
24045440,1,5,Premise,Premise,none,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology."
24045440,1,6,Premise,Claim,none,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).,Fecal incontinence seems to be a problem.
24045440,2,1,Premise,Premise,none,Some patients reported symptoms of fecal incontinence.,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).
24045440,2,3,Premise,Premise,none,Some patients reported symptoms of fecal incontinence.,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144)."
24045440,2,4,Premise,Claim,none,Some patients reported symptoms of fecal incontinence.,The outcome of these patients remains unsatisfactory.
24045440,2,5,Premise,Premise,none,Some patients reported symptoms of fecal incontinence.,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology."
24045440,2,6,Premise,Claim,support,Some patients reported symptoms of fecal incontinence.,Fecal incontinence seems to be a problem.
24045440,3,1,Premise,Premise,none,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144).",Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).
24045440,3,2,Premise,Premise,none,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144).",Some patients reported symptoms of fecal incontinence.
24045440,3,4,Premise,Claim,none,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144).",The outcome of these patients remains unsatisfactory.
24045440,3,5,Premise,Premise,none,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144).","Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology."
24045440,3,6,Premise,Claim,support,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144).",Fecal incontinence seems to be a problem.
24045440,4,1,Claim,Premise,none,The outcome of these patients remains unsatisfactory.,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).
24045440,4,2,Claim,Premise,none,The outcome of these patients remains unsatisfactory.,Some patients reported symptoms of fecal incontinence.
24045440,4,3,Claim,Premise,none,The outcome of these patients remains unsatisfactory.,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144)."
24045440,4,5,Claim,Premise,none,The outcome of these patients remains unsatisfactory.,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology."
24045440,4,6,Claim,Claim,none,The outcome of these patients remains unsatisfactory.,Fecal incontinence seems to be a problem.
24045440,5,1,Premise,Premise,none,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology.",Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).
24045440,5,2,Premise,Premise,none,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology.",Some patients reported symptoms of fecal incontinence.
24045440,5,3,Premise,Premise,none,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology.","The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144)."
24045440,5,4,Premise,Claim,support,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology.",The outcome of these patients remains unsatisfactory.
24045440,5,6,Premise,Claim,none,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology.",Fecal incontinence seems to be a problem.
24045440,6,1,Claim,Premise,none,Fecal incontinence seems to be a problem.,Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013).
24045440,6,2,Claim,Premise,none,Fecal incontinence seems to be a problem.,Some patients reported symptoms of fecal incontinence.
24045440,6,3,Claim,Premise,none,Fecal incontinence seems to be a problem.,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144)."
24045440,6,4,Claim,Claim,support,Fecal incontinence seems to be a problem.,The outcome of these patients remains unsatisfactory.
24045440,6,5,Claim,Premise,none,Fecal incontinence seems to be a problem.,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology."
22842422,1,2,Premise,Premise,none,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis.",Quality of life was similar in the two groups.
22842422,1,3,Premise,Claim,support,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis.",The permanent expander method failed significantly as a one-stage procedure.
22842422,1,4,Premise,Claim,none,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis.",The crescent two-stage method gave the most acceptable results both objectively and subjectively.
22842422,2,1,Premise,Premise,none,Quality of life was similar in the two groups.,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis."
22842422,2,3,Premise,Claim,none,Quality of life was similar in the two groups.,The permanent expander method failed significantly as a one-stage procedure.
22842422,2,4,Premise,Claim,none,Quality of life was similar in the two groups.,The crescent two-stage method gave the most acceptable results both objectively and subjectively.
22842422,3,1,Claim,Premise,none,The permanent expander method failed significantly as a one-stage procedure.,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis."
22842422,3,2,Claim,Premise,none,The permanent expander method failed significantly as a one-stage procedure.,Quality of life was similar in the two groups.
22842422,3,4,Claim,Claim,none,The permanent expander method failed significantly as a one-stage procedure.,The crescent two-stage method gave the most acceptable results both objectively and subjectively.
22842422,4,1,Claim,Premise,none,The crescent two-stage method gave the most acceptable results both objectively and subjectively.,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis."
22842422,4,2,Claim,Premise,none,The crescent two-stage method gave the most acceptable results both objectively and subjectively.,Quality of life was similar in the two groups.
22842422,4,3,Claim,Claim,none,The crescent two-stage method gave the most acceptable results both objectively and subjectively.,The permanent expander method failed significantly as a one-stage procedure.
11788911,1,2,Premise,Premise,none,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.","The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22)."
11788911,1,3,Premise,Premise,none,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.","The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia."
11788911,1,4,Premise,Claim,none,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.",the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
11788911,1,5,Premise,Claim,support,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.",this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
11788911,1,6,Premise,MajorClaim,none,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.",this regimen could not be recommended for a phase III randomized study.
11788911,2,1,Premise,Premise,none,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).","At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free."
11788911,2,3,Premise,Premise,none,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).","The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia."
11788911,2,4,Premise,Claim,none,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).",the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
11788911,2,5,Premise,Claim,support,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).",this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
11788911,2,6,Premise,MajorClaim,none,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).",this regimen could not be recommended for a phase III randomized study.
11788911,3,1,Premise,Premise,none,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.","At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free."
11788911,3,2,Premise,Premise,none,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.","The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22)."
11788911,3,4,Premise,Claim,none,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.",the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
11788911,3,5,Premise,Claim,support,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.",this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
11788911,3,6,Premise,MajorClaim,none,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.",this regimen could not be recommended for a phase III randomized study.
11788911,4,1,Claim,Premise,none,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free."
11788911,4,2,Claim,Premise,none,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22)."
11788911,4,3,Claim,Premise,none,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia."
11788911,4,5,Claim,Claim,none,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
11788911,4,6,Claim,MajorClaim,none,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.,this regimen could not be recommended for a phase III randomized study.
11788911,5,1,Claim,Premise,none,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free."
11788911,5,2,Claim,Premise,none,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22)."
11788911,5,3,Claim,Premise,none,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia."
11788911,5,4,Claim,Claim,none,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
11788911,5,6,Claim,MajorClaim,support,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;,this regimen could not be recommended for a phase III randomized study.
11788911,6,1,MajorClaim,Premise,none,this regimen could not be recommended for a phase III randomized study.,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free."
11788911,6,2,MajorClaim,Premise,none,this regimen could not be recommended for a phase III randomized study.,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22)."
11788911,6,3,MajorClaim,Premise,none,this regimen could not be recommended for a phase III randomized study.,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia."
11788911,6,4,MajorClaim,Claim,none,this regimen could not be recommended for a phase III randomized study.,the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
11788911,6,5,MajorClaim,Claim,none,this regimen could not be recommended for a phase III randomized study.,this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
11843249,1,2,Premise,Premise,none,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004).","The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06)."
11843249,1,3,Premise,Premise,none,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004).","The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone."
11843249,1,4,Premise,Premise,none,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004).",Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).
11843249,1,5,Premise,Premise,none,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004).",There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
11843249,1,6,Premise,Claim,support,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004).",The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
11843249,2,1,Premise,Premise,none,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06).","The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004)."
11843249,2,3,Premise,Premise,none,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06).","The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone."
11843249,2,4,Premise,Premise,none,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06).",Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).
11843249,2,5,Premise,Premise,none,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06).",There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
11843249,2,6,Premise,Claim,support,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06).",The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
11843249,3,1,Premise,Premise,none,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone.","The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004)."
11843249,3,2,Premise,Premise,none,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone.","The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06)."
11843249,3,4,Premise,Premise,none,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone.",Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).
11843249,3,5,Premise,Premise,none,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone.",There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
11843249,3,6,Premise,Claim,support,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone.",The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
11843249,4,1,Premise,Premise,none,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004)."
11843249,4,2,Premise,Premise,none,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06)."
11843249,4,3,Premise,Premise,none,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone."
11843249,4,5,Premise,Premise,none,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
11843249,4,6,Premise,Claim,support,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
11843249,5,1,Premise,Premise,none,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004)."
11843249,5,2,Premise,Premise,none,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06)."
11843249,5,3,Premise,Premise,none,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone."
11843249,5,4,Premise,Premise,none,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).
11843249,5,6,Premise,Claim,none,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
11843249,6,1,Claim,Premise,none,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004)."
11843249,6,2,Claim,Premise,none,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06)."
11843249,6,3,Claim,Premise,none,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone."
11843249,6,4,Claim,Premise,none,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.,Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06).
11843249,6,5,Claim,Premise,none,The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.,There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
11896110,1,2,Claim,Claim,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).",Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,1,3,Claim,Premise,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).","At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,1,4,Claim,Premise,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).","In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,1,5,Claim,Premise,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).","In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,1,6,Claim,Premise,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).",Treatment-related toxicity was fairly similar in both arms.
11896110,1,7,Claim,Claim,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).","The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,1,8,Claim,Claim,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).","However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,1,9,Claim,Claim,none,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).",our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,2,1,Claim,Claim,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,2,3,Claim,Premise,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,2,4,Claim,Premise,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,2,5,Claim,Premise,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,2,6,Claim,Premise,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,Treatment-related toxicity was fairly similar in both arms.
11896110,2,7,Claim,Claim,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,2,8,Claim,Claim,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,2,9,Claim,Claim,none,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,3,1,Premise,Claim,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.","Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,3,2,Premise,Claim,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.",Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,3,4,Premise,Premise,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.","In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,3,5,Premise,Premise,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.","In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,3,6,Premise,Premise,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.",Treatment-related toxicity was fairly similar in both arms.
11896110,3,7,Premise,Claim,support,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.","The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,3,8,Premise,Claim,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.","However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,3,9,Premise,Claim,none,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively.",our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,4,1,Premise,Claim,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.","Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,4,2,Premise,Claim,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.",Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,4,3,Premise,Premise,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.","At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,4,5,Premise,Premise,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.","In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,4,6,Premise,Premise,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.",Treatment-related toxicity was fairly similar in both arms.
11896110,4,7,Premise,Claim,support,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.","The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,4,8,Premise,Claim,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.","However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,4,9,Premise,Claim,none,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria.",our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,5,1,Premise,Claim,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.","Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,5,2,Premise,Claim,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.",Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,5,3,Premise,Premise,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.","At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,5,4,Premise,Premise,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.","In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,5,6,Premise,Premise,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.",Treatment-related toxicity was fairly similar in both arms.
11896110,5,7,Premise,Claim,support,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.","The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,5,8,Premise,Claim,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.","However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,5,9,Premise,Claim,none,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded.",our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,6,1,Premise,Claim,none,Treatment-related toxicity was fairly similar in both arms.,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,6,2,Premise,Claim,none,Treatment-related toxicity was fairly similar in both arms.,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,6,3,Premise,Premise,none,Treatment-related toxicity was fairly similar in both arms.,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,6,4,Premise,Premise,none,Treatment-related toxicity was fairly similar in both arms.,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,6,5,Premise,Premise,none,Treatment-related toxicity was fairly similar in both arms.,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,6,7,Premise,Claim,none,Treatment-related toxicity was fairly similar in both arms.,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,6,8,Premise,Claim,none,Treatment-related toxicity was fairly similar in both arms.,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,6,9,Premise,Claim,support,Treatment-related toxicity was fairly similar in both arms.,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,7,1,Claim,Claim,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.","Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,7,2,Claim,Claim,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.",Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,7,3,Claim,Premise,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.","At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,7,4,Claim,Premise,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.","In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,7,5,Claim,Premise,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.","In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,7,6,Claim,Premise,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.",Treatment-related toxicity was fairly similar in both arms.
11896110,7,8,Claim,Claim,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.","However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,7,9,Claim,Claim,none,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR.",our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,8,1,Claim,Claim,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.","Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,8,2,Claim,Claim,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.",Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,8,3,Claim,Premise,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.","At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,8,4,Claim,Premise,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.","In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,8,5,Claim,Premise,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.","In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,8,6,Claim,Premise,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.",Treatment-related toxicity was fairly similar in both arms.
11896110,8,7,Claim,Claim,attack,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.","The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,8,9,Claim,Claim,none,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature.",our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.
11896110,9,1,Claim,Claim,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,9,2,Claim,Claim,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting.
11896110,9,3,Claim,Premise,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,9,4,Claim,Premise,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,9,5,Claim,Premise,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,9,6,Claim,Premise,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,Treatment-related toxicity was fairly similar in both arms.
11896110,9,7,Claim,Claim,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,9,8,Claim,Claim,none,our treatment schedule was carried out on outpatients and had an acceptable level of toxicity.,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
20351334,1,2,Premise,Premise,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).","ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,1,3,Premise,Premise,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).",No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,1,4,Premise,Premise,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).",No unexpected adverse events were observed.
20351334,1,5,Premise,Premise,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).","Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,1,6,Premise,Claim,support,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).",This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,1,7,Premise,Claim,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).","Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,1,8,Premise,Claim,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).",the overall toxicity profile of vinflunine was manageable.
20351334,1,9,Premise,MajorClaim,none,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199).",VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,2,1,Premise,Premise,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.","Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,2,3,Premise,Premise,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.",No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,2,4,Premise,Premise,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.",No unexpected adverse events were observed.
20351334,2,5,Premise,Premise,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.","Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,2,6,Premise,Claim,support,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.",This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,2,7,Premise,Claim,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.","Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,2,8,Premise,Claim,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.",the overall toxicity profile of vinflunine was manageable.
20351334,2,9,Premise,MajorClaim,none,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively.",VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,3,1,Premise,Premise,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,3,2,Premise,Premise,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,3,4,Premise,Premise,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,No unexpected adverse events were observed.
20351334,3,5,Premise,Premise,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,3,6,Premise,Claim,support,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,3,7,Premise,Claim,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,3,8,Premise,Claim,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,the overall toxicity profile of vinflunine was manageable.
20351334,3,9,Premise,MajorClaim,none,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).,VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,4,1,Premise,Premise,none,No unexpected adverse events were observed.,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,4,2,Premise,Premise,none,No unexpected adverse events were observed.,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,4,3,Premise,Premise,none,No unexpected adverse events were observed.,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,4,5,Premise,Premise,none,No unexpected adverse events were observed.,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,4,6,Premise,Claim,none,No unexpected adverse events were observed.,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,4,7,Premise,Claim,none,No unexpected adverse events were observed.,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,4,8,Premise,Claim,support,No unexpected adverse events were observed.,the overall toxicity profile of vinflunine was manageable.
20351334,4,9,Premise,MajorClaim,none,No unexpected adverse events were observed.,VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,5,1,Premise,Premise,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.","Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,5,2,Premise,Premise,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.","ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,5,3,Premise,Premise,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.",No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,5,4,Premise,Premise,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.",No unexpected adverse events were observed.
20351334,5,6,Premise,Claim,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.",This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,5,7,Premise,Claim,support,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.","Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,5,8,Premise,Claim,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.",the overall toxicity profile of vinflunine was manageable.
20351334,5,9,Premise,MajorClaim,none,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed.",VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,6,1,Claim,Premise,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,6,2,Claim,Premise,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,6,3,Claim,Premise,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,6,4,Claim,Premise,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,No unexpected adverse events were observed.
20351334,6,5,Claim,Premise,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,6,7,Claim,Claim,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,6,8,Claim,Claim,none,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,the overall toxicity profile of vinflunine was manageable.
20351334,6,9,Claim,MajorClaim,support,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.,VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,7,1,Claim,Premise,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)","Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,7,2,Claim,Premise,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)","ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,7,3,Claim,Premise,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)",No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,7,4,Claim,Premise,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)",No unexpected adverse events were observed.
20351334,7,5,Claim,Premise,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)","Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,7,6,Claim,Claim,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)",This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,7,8,Claim,Claim,attack,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)",the overall toxicity profile of vinflunine was manageable.
20351334,7,9,Claim,MajorClaim,none,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)",VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,8,1,Claim,Premise,none,the overall toxicity profile of vinflunine was manageable.,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,8,2,Claim,Premise,none,the overall toxicity profile of vinflunine was manageable.,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,8,3,Claim,Premise,none,the overall toxicity profile of vinflunine was manageable.,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,8,4,Claim,Premise,none,the overall toxicity profile of vinflunine was manageable.,No unexpected adverse events were observed.
20351334,8,5,Claim,Premise,none,the overall toxicity profile of vinflunine was manageable.,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,8,6,Claim,Claim,none,the overall toxicity profile of vinflunine was manageable.,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,8,7,Claim,Claim,none,the overall toxicity profile of vinflunine was manageable.,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,8,9,Claim,MajorClaim,support,the overall toxicity profile of vinflunine was manageable.,VFL may be another option in the second-line treatment of patients with advanced NSCLC.
20351334,9,1,MajorClaim,Premise,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,9,2,MajorClaim,Premise,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,9,3,MajorClaim,Premise,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung).
20351334,9,4,MajorClaim,Premise,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,No unexpected adverse events were observed.
20351334,9,5,MajorClaim,Premise,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,9,6,MajorClaim,Claim,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel.
20351334,9,7,MajorClaim,Claim,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,9,8,MajorClaim,Claim,none,VFL may be another option in the second-line treatment of patients with advanced NSCLC.,the overall toxicity profile of vinflunine was manageable.
10735891,1,2,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,1,3,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,1,4,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,1,5,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,1,6,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,1,7,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,1,8,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,overall survival was similar.
10735891,1,9,Claim,Premise,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,1,10,Claim,Claim,none,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,2,1,Premise,Claim,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,2,3,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,2,4,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,2,5,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,2,6,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,2,7,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,2,8,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,overall survival was similar.
10735891,2,9,Premise,Premise,none,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,2,10,Premise,Claim,support,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,3,1,Premise,Claim,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),",Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,3,2,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),",Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,3,4,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),","duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,3,5,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),","Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,3,6,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),",the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,3,7,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),","Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,3,8,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),",overall survival was similar.
10735891,3,9,Premise,Premise,none,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),",Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,3,10,Premise,Claim,support,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),",Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,4,1,Premise,Claim,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).",Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,4,2,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).",Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,4,3,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).","Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,4,5,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).","Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,4,6,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).",the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,4,7,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).","Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,4,8,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).",overall survival was similar.
10735891,4,9,Premise,Premise,none,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).",Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,4,10,Premise,Claim,support,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).",Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,5,1,Premise,Claim,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)",Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,5,2,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)",Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,5,3,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)","Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,5,4,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)","duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,5,6,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)",the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,5,7,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)","Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,5,8,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)",overall survival was similar.
10735891,5,9,Premise,Premise,none,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)",Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,5,10,Premise,Claim,support,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)",Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,6,1,Premise,Claim,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,6,2,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,6,3,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,6,4,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,6,5,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,6,7,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,6,8,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,overall survival was similar.
10735891,6,9,Premise,Premise,none,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,6,10,Premise,Claim,support,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,7,1,Premise,Claim,none,"Neither quality of life nor performance status was decreased by suramin treatment,",Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,7,2,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,",Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,7,3,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,","Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,7,4,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,","duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,7,5,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,","Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,7,6,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,",the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,7,8,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,",overall survival was similar.
10735891,7,9,Premise,Premise,none,"Neither quality of life nor performance status was decreased by suramin treatment,",Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,7,10,Premise,Claim,none,"Neither quality of life nor performance status was decreased by suramin treatment,",Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,8,1,Premise,Claim,none,overall survival was similar.,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,8,2,Premise,Premise,none,overall survival was similar.,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,8,3,Premise,Premise,none,overall survival was similar.,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,8,4,Premise,Premise,none,overall survival was similar.,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,8,5,Premise,Premise,none,overall survival was similar.,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,8,6,Premise,Premise,none,overall survival was similar.,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,8,7,Premise,Premise,none,overall survival was similar.,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,8,9,Premise,Premise,none,overall survival was similar.,Most adverse events were of mild or moderate intensity and were easily managed medically.
10735891,8,10,Premise,Claim,none,overall survival was similar.,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,9,1,Premise,Claim,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,9,2,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,9,3,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,9,4,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,9,5,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,9,6,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,9,7,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,9,8,Premise,Premise,none,Most adverse events were of mild or moderate intensity and were easily managed medically.,overall survival was similar.
10735891,9,10,Premise,Claim,support,Most adverse events were of mild or moderate intensity and were easily managed medically.,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
10735891,10,1,Claim,Claim,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
10735891,10,2,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
10735891,10,3,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,10,4,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,10,5,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,10,6,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
10735891,10,7,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,10,8,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,overall survival was similar.
10735891,10,9,Claim,Premise,none,Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.,Most adverse events were of mild or moderate intensity and were easily managed medically.
9137798,1,2,Premise,Premise,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.","A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,1,3,Premise,Premise,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.","Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,1,4,Premise,Premise,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.",Improvements in QoL occurred early within four weeks and were sustained.
9137798,1,5,Premise,Premise,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.","No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,1,6,Premise,Premise,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.",Side effects of therapy were minor and did not differ significantly across treatments.
9137798,1,7,Premise,Claim,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.",Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,1,8,Premise,Claim,support,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.","It improves appetite, mood and overall quality of life in these patients,"
9137798,1,9,Premise,Claim,none,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend.",although not through a direct effect on nutritional status.
9137798,2,1,Premise,Premise,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).","Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,2,3,Premise,Premise,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).","Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,2,4,Premise,Premise,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).",Improvements in QoL occurred early within four weeks and were sustained.
9137798,2,5,Premise,Premise,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).","No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,2,6,Premise,Premise,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).",Side effects of therapy were minor and did not differ significantly across treatments.
9137798,2,7,Premise,Claim,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).",Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,2,8,Premise,Claim,support,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).","It improves appetite, mood and overall quality of life in these patients,"
9137798,2,9,Premise,Claim,none,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001).",although not through a direct effect on nutritional status.
9137798,3,1,Premise,Premise,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).","Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,3,2,Premise,Premise,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).","A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,3,4,Premise,Premise,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).",Improvements in QoL occurred early within four weeks and were sustained.
9137798,3,5,Premise,Premise,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).","No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,3,6,Premise,Premise,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).",Side effects of therapy were minor and did not differ significantly across treatments.
9137798,3,7,Premise,Claim,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).",Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,3,8,Premise,Claim,support,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).","It improves appetite, mood and overall quality of life in these patients,"
9137798,3,9,Premise,Claim,none,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002).",although not through a direct effect on nutritional status.
9137798,4,1,Premise,Premise,none,Improvements in QoL occurred early within four weeks and were sustained.,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,4,2,Premise,Premise,none,Improvements in QoL occurred early within four weeks and were sustained.,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,4,3,Premise,Premise,none,Improvements in QoL occurred early within four weeks and were sustained.,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,4,5,Premise,Premise,none,Improvements in QoL occurred early within four weeks and were sustained.,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,4,6,Premise,Premise,none,Improvements in QoL occurred early within four weeks and were sustained.,Side effects of therapy were minor and did not differ significantly across treatments.
9137798,4,7,Premise,Claim,none,Improvements in QoL occurred early within four weeks and were sustained.,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,4,8,Premise,Claim,support,Improvements in QoL occurred early within four weeks and were sustained.,"It improves appetite, mood and overall quality of life in these patients,"
9137798,4,9,Premise,Claim,none,Improvements in QoL occurred early within four weeks and were sustained.,although not through a direct effect on nutritional status.
9137798,5,1,Premise,Premise,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).","Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,5,2,Premise,Premise,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).","A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,5,3,Premise,Premise,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).","Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,5,4,Premise,Premise,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).",Improvements in QoL occurred early within four weeks and were sustained.
9137798,5,6,Premise,Premise,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).",Side effects of therapy were minor and did not differ significantly across treatments.
9137798,5,7,Premise,Claim,support,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).",Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,5,8,Premise,Claim,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).","It improves appetite, mood and overall quality of life in these patients,"
9137798,5,9,Premise,Claim,none,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29).",although not through a direct effect on nutritional status.
9137798,6,1,Premise,Premise,none,Side effects of therapy were minor and did not differ significantly across treatments.,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,6,2,Premise,Premise,none,Side effects of therapy were minor and did not differ significantly across treatments.,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,6,3,Premise,Premise,none,Side effects of therapy were minor and did not differ significantly across treatments.,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,6,4,Premise,Premise,none,Side effects of therapy were minor and did not differ significantly across treatments.,Improvements in QoL occurred early within four weeks and were sustained.
9137798,6,5,Premise,Premise,none,Side effects of therapy were minor and did not differ significantly across treatments.,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,6,7,Premise,Claim,support,Side effects of therapy were minor and did not differ significantly across treatments.,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,6,8,Premise,Claim,none,Side effects of therapy were minor and did not differ significantly across treatments.,"It improves appetite, mood and overall quality of life in these patients,"
9137798,6,9,Premise,Claim,none,Side effects of therapy were minor and did not differ significantly across treatments.,although not through a direct effect on nutritional status.
9137798,7,1,Claim,Premise,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,7,2,Claim,Premise,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,7,3,Claim,Premise,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,7,4,Claim,Premise,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,Improvements in QoL occurred early within four weeks and were sustained.
9137798,7,5,Claim,Premise,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,7,6,Claim,Premise,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,Side effects of therapy were minor and did not differ significantly across treatments.
9137798,7,8,Claim,Claim,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,"It improves appetite, mood and overall quality of life in these patients,"
9137798,7,9,Claim,Claim,none,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.,although not through a direct effect on nutritional status.
9137798,8,1,Claim,Premise,none,"It improves appetite, mood and overall quality of life in these patients,","Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,8,2,Claim,Premise,none,"It improves appetite, mood and overall quality of life in these patients,","A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,8,3,Claim,Premise,none,"It improves appetite, mood and overall quality of life in these patients,","Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,8,4,Claim,Premise,none,"It improves appetite, mood and overall quality of life in these patients,",Improvements in QoL occurred early within four weeks and were sustained.
9137798,8,5,Claim,Premise,none,"It improves appetite, mood and overall quality of life in these patients,","No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,8,6,Claim,Premise,none,"It improves appetite, mood and overall quality of life in these patients,",Side effects of therapy were minor and did not differ significantly across treatments.
9137798,8,7,Claim,Claim,support,"It improves appetite, mood and overall quality of life in these patients,",Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,8,9,Claim,Claim,none,"It improves appetite, mood and overall quality of life in these patients,",although not through a direct effect on nutritional status.
9137798,9,1,Claim,Premise,none,although not through a direct effect on nutritional status.,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,9,2,Claim,Premise,none,although not through a direct effect on nutritional status.,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,9,3,Claim,Premise,none,although not through a direct effect on nutritional status.,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,9,4,Claim,Premise,none,although not through a direct effect on nutritional status.,Improvements in QoL occurred early within four weeks and were sustained.
9137798,9,5,Claim,Premise,none,although not through a direct effect on nutritional status.,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,9,6,Claim,Premise,none,although not through a direct effect on nutritional status.,Side effects of therapy were minor and did not differ significantly across treatments.
9137798,9,7,Claim,Claim,none,although not through a direct effect on nutritional status.,Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer.
9137798,9,8,Claim,Claim,attack,although not through a direct effect on nutritional status.,"It improves appetite, mood and overall quality of life in these patients,"
11830607,1,2,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,1,3,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,1,4,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Elderly women lost more weight than younger women (P =.006).
11830607,1,5,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Other toxic effects were similar in older and younger patients.
11830607,1,6,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.","The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,1,7,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Baseline quality-of-life and treatment-outcome indices were similar.
11830607,1,8,Claim,Premise,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Equivalent declines over time in functional well-being occurred in both groups.
11830607,1,9,Claim,Claim,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.","Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,1,10,Claim,Claim,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,1,11,Claim,Claim,none,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy.",Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,2,1,Premise,Claim,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,2,3,Premise,Premise,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,2,4,Premise,Premise,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,Elderly women lost more weight than younger women (P =.006).
11830607,2,5,Premise,Premise,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,Other toxic effects were similar in older and younger patients.
11830607,2,6,Premise,Premise,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,2,7,Premise,Premise,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,2,8,Premise,Premise,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,Equivalent declines over time in functional well-being occurred in both groups.
11830607,2,9,Premise,Claim,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,2,10,Premise,Claim,support,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,2,11,Premise,Claim,none,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,3,1,Premise,Claim,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,3,2,Premise,Premise,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,3,4,Premise,Premise,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,Elderly women lost more weight than younger women (P =.006).
11830607,3,5,Premise,Premise,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,Other toxic effects were similar in older and younger patients.
11830607,3,6,Premise,Premise,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,3,7,Premise,Premise,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,3,8,Premise,Premise,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,Equivalent declines over time in functional well-being occurred in both groups.
11830607,3,9,Premise,Claim,attack,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,3,10,Premise,Claim,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,3,11,Premise,Claim,none,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,4,1,Premise,Claim,none,Elderly women lost more weight than younger women (P =.006).,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,4,2,Premise,Premise,none,Elderly women lost more weight than younger women (P =.006).,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,4,3,Premise,Premise,none,Elderly women lost more weight than younger women (P =.006).,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,4,5,Premise,Premise,none,Elderly women lost more weight than younger women (P =.006).,Other toxic effects were similar in older and younger patients.
11830607,4,6,Premise,Premise,none,Elderly women lost more weight than younger women (P =.006).,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,4,7,Premise,Premise,none,Elderly women lost more weight than younger women (P =.006).,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,4,8,Premise,Premise,none,Elderly women lost more weight than younger women (P =.006).,Equivalent declines over time in functional well-being occurred in both groups.
11830607,4,9,Premise,Claim,none,Elderly women lost more weight than younger women (P =.006).,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,4,10,Premise,Claim,none,Elderly women lost more weight than younger women (P =.006).,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,4,11,Premise,Claim,none,Elderly women lost more weight than younger women (P =.006).,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,5,1,Premise,Claim,none,Other toxic effects were similar in older and younger patients.,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,5,2,Premise,Premise,none,Other toxic effects were similar in older and younger patients.,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,5,3,Premise,Premise,none,Other toxic effects were similar in older and younger patients.,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,5,4,Premise,Premise,none,Other toxic effects were similar in older and younger patients.,Elderly women lost more weight than younger women (P =.006).
11830607,5,6,Premise,Premise,none,Other toxic effects were similar in older and younger patients.,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,5,7,Premise,Premise,none,Other toxic effects were similar in older and younger patients.,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,5,8,Premise,Premise,none,Other toxic effects were similar in older and younger patients.,Equivalent declines over time in functional well-being occurred in both groups.
11830607,5,9,Premise,Claim,support,Other toxic effects were similar in older and younger patients.,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,5,10,Premise,Claim,none,Other toxic effects were similar in older and younger patients.,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,5,11,Premise,Claim,none,Other toxic effects were similar in older and younger patients.,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,6,1,Premise,Claim,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.","Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,6,2,Premise,Premise,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,6,3,Premise,Premise,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,6,4,Premise,Premise,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Elderly women lost more weight than younger women (P =.006).
11830607,6,5,Premise,Premise,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Other toxic effects were similar in older and younger patients.
11830607,6,7,Premise,Premise,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Baseline quality-of-life and treatment-outcome indices were similar.
11830607,6,8,Premise,Premise,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Equivalent declines over time in functional well-being occurred in both groups.
11830607,6,9,Premise,Claim,support,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.","Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,6,10,Premise,Claim,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,6,11,Premise,Claim,none,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older.",Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,7,1,Premise,Claim,none,Baseline quality-of-life and treatment-outcome indices were similar.,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,7,2,Premise,Premise,none,Baseline quality-of-life and treatment-outcome indices were similar.,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,7,3,Premise,Premise,none,Baseline quality-of-life and treatment-outcome indices were similar.,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,7,4,Premise,Premise,none,Baseline quality-of-life and treatment-outcome indices were similar.,Elderly women lost more weight than younger women (P =.006).
11830607,7,5,Premise,Premise,none,Baseline quality-of-life and treatment-outcome indices were similar.,Other toxic effects were similar in older and younger patients.
11830607,7,6,Premise,Premise,none,Baseline quality-of-life and treatment-outcome indices were similar.,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,7,8,Premise,Premise,none,Baseline quality-of-life and treatment-outcome indices were similar.,Equivalent declines over time in functional well-being occurred in both groups.
11830607,7,9,Premise,Claim,none,Baseline quality-of-life and treatment-outcome indices were similar.,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,7,10,Premise,Claim,none,Baseline quality-of-life and treatment-outcome indices were similar.,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,7,11,Premise,Claim,none,Baseline quality-of-life and treatment-outcome indices were similar.,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,8,1,Premise,Claim,none,Equivalent declines over time in functional well-being occurred in both groups.,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,8,2,Premise,Premise,none,Equivalent declines over time in functional well-being occurred in both groups.,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,8,3,Premise,Premise,none,Equivalent declines over time in functional well-being occurred in both groups.,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,8,4,Premise,Premise,none,Equivalent declines over time in functional well-being occurred in both groups.,Elderly women lost more weight than younger women (P =.006).
11830607,8,5,Premise,Premise,none,Equivalent declines over time in functional well-being occurred in both groups.,Other toxic effects were similar in older and younger patients.
11830607,8,6,Premise,Premise,none,Equivalent declines over time in functional well-being occurred in both groups.,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,8,7,Premise,Premise,none,Equivalent declines over time in functional well-being occurred in both groups.,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,8,9,Premise,Claim,none,Equivalent declines over time in functional well-being occurred in both groups.,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,8,10,Premise,Claim,none,Equivalent declines over time in functional well-being occurred in both groups.,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,8,11,Premise,Claim,none,Equivalent declines over time in functional well-being occurred in both groups.,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,9,1,Claim,Claim,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,","Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,9,2,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,9,3,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,9,4,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Elderly women lost more weight than younger women (P =.006).
11830607,9,5,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Other toxic effects were similar in older and younger patients.
11830607,9,6,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,","The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,9,7,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Baseline quality-of-life and treatment-outcome indices were similar.
11830607,9,8,Claim,Premise,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Equivalent declines over time in functional well-being occurred in both groups.
11830607,9,10,Claim,Claim,none,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
11830607,9,11,Claim,Claim,support,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,",Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,10,1,Claim,Claim,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,10,2,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,10,3,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,10,4,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Elderly women lost more weight than younger women (P =.006).
11830607,10,5,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Other toxic effects were similar in older and younger patients.
11830607,10,6,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,10,7,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,10,8,Claim,Premise,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Equivalent declines over time in functional well-being occurred in both groups.
11830607,10,9,Claim,Claim,attack,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,10,11,Claim,Claim,none,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.,Advanced age alone should not preclude appropriate NSCLC treatment.
11830607,11,1,Claim,Claim,none,Advanced age alone should not preclude appropriate NSCLC treatment.,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,11,2,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02).
11830607,11,3,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men.
11830607,11,4,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,Elderly women lost more weight than younger women (P =.006).
11830607,11,5,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,Other toxic effects were similar in older and younger patients.
11830607,11,6,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,11,7,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,Baseline quality-of-life and treatment-outcome indices were similar.
11830607,11,8,Claim,Premise,none,Advanced age alone should not preclude appropriate NSCLC treatment.,Equivalent declines over time in functional well-being occurred in both groups.
11830607,11,9,Claim,Claim,none,Advanced age alone should not preclude appropriate NSCLC treatment.,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,11,10,Claim,Claim,none,Advanced age alone should not preclude appropriate NSCLC treatment.,although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.
23404211,1,2,Premise,Premise,none,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).","Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,1,3,Premise,Premise,none,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).","Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,1,4,Premise,Premise,none,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).","The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,1,5,Premise,Premise,none,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).",Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,1,6,Premise,Premise,none,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).",Quality of life was similar between treatment arms in Asian patients.
23404211,1,7,Premise,Claim,support,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).",Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
23404211,1,8,Premise,Claim,none,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94).","This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,2,1,Premise,Premise,none,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).","Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,2,3,Premise,Premise,none,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).","Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,2,4,Premise,Premise,none,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).","The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,2,5,Premise,Premise,none,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).",Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,2,6,Premise,Premise,none,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).",Quality of life was similar between treatment arms in Asian patients.
23404211,2,7,Premise,Claim,support,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).",Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
23404211,2,8,Premise,Claim,none,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50).","This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,3,1,Premise,Premise,none,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.","Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,3,2,Premise,Premise,none,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.","Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,3,4,Premise,Premise,none,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.","The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,3,5,Premise,Premise,none,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.",Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,3,6,Premise,Premise,none,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.",Quality of life was similar between treatment arms in Asian patients.
23404211,3,7,Premise,Claim,support,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.",Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
23404211,3,8,Premise,Claim,none,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients.","This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,4,1,Premise,Premise,none,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.","Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,4,2,Premise,Premise,none,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.","Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,4,3,Premise,Premise,none,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.","Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,4,5,Premise,Premise,none,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.",Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,4,6,Premise,Premise,none,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.",Quality of life was similar between treatment arms in Asian patients.
23404211,4,7,Premise,Claim,support,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.",Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
23404211,4,8,Premise,Claim,none,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients.","This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,5,1,Premise,Premise,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,5,2,Premise,Premise,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,5,3,Premise,Premise,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,5,4,Premise,Premise,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,5,6,Premise,Premise,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,Quality of life was similar between treatment arms in Asian patients.
23404211,5,7,Premise,Claim,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
23404211,5,8,Premise,Claim,none,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,6,1,Premise,Premise,none,Quality of life was similar between treatment arms in Asian patients.,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,6,2,Premise,Premise,none,Quality of life was similar between treatment arms in Asian patients.,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,6,3,Premise,Premise,none,Quality of life was similar between treatment arms in Asian patients.,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,6,4,Premise,Premise,none,Quality of life was similar between treatment arms in Asian patients.,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,6,5,Premise,Premise,none,Quality of life was similar between treatment arms in Asian patients.,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,6,7,Premise,Claim,support,Quality of life was similar between treatment arms in Asian patients.,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
23404211,6,8,Premise,Claim,none,Quality of life was similar between treatment arms in Asian patients.,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,7,1,Claim,Premise,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,7,2,Claim,Premise,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,7,3,Claim,Premise,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,7,4,Claim,Premise,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,7,5,Claim,Premise,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,7,6,Claim,Premise,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,Quality of life was similar between treatment arms in Asian patients.
23404211,7,8,Claim,Claim,none,Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23404211,8,1,Claim,Premise,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.","Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,8,2,Claim,Premise,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.","Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,8,3,Claim,Premise,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.","Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,8,4,Claim,Premise,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.","The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,8,5,Claim,Premise,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.",Grade 1/2 interstitial lung disease occurred more frequently in Asian patients.
23404211,8,6,Claim,Premise,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.",Quality of life was similar between treatment arms in Asian patients.
23404211,8,7,Claim,Claim,none,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.",Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles.
22868247,1,2,Premise,Premise,none,There was no difference in overall or cancer-specific survival between the 2 arms.,There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.
22868247,1,3,Premise,Premise,none,There was no difference in overall or cancer-specific survival between the 2 arms.,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous."
22868247,1,4,Premise,Premise,none,There was no difference in overall or cancer-specific survival between the 2 arms.,The main limitation of this study is the small sample size.
22868247,1,5,Premise,Claim,support,There was no difference in overall or cancer-specific survival between the 2 arms.,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes."
22868247,2,1,Premise,Premise,none,There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.,There was no difference in overall or cancer-specific survival between the 2 arms.
22868247,2,3,Premise,Premise,none,There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous."
22868247,2,4,Premise,Premise,none,There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.,The main limitation of this study is the small sample size.
22868247,2,5,Premise,Claim,support,There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes."
22868247,3,1,Premise,Premise,none,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous.",There was no difference in overall or cancer-specific survival between the 2 arms.
22868247,3,2,Premise,Premise,none,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous.",There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.
22868247,3,4,Premise,Premise,none,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous.",The main limitation of this study is the small sample size.
22868247,3,5,Premise,Claim,support,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous.","We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes."
22868247,4,1,Premise,Premise,none,The main limitation of this study is the small sample size.,There was no difference in overall or cancer-specific survival between the 2 arms.
22868247,4,2,Premise,Premise,none,The main limitation of this study is the small sample size.,There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.
22868247,4,3,Premise,Premise,none,The main limitation of this study is the small sample size.,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous."
22868247,4,5,Premise,Claim,attack,The main limitation of this study is the small sample size.,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes."
22868247,5,1,Claim,Premise,none,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes.",There was no difference in overall or cancer-specific survival between the 2 arms.
22868247,5,2,Claim,Premise,none,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes.",There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months.
22868247,5,3,Claim,Premise,none,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes.","The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous."
22868247,5,4,Claim,Premise,none,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes.",The main limitation of this study is the small sample size.
22945882,1,2,Premise,Premise,none,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).,No significant improvement was observed in the placebo group (n = 10).
22945882,1,3,Premise,Premise,none,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.
22945882,1,4,Premise,Premise,none,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,1,5,Premise,Premise,none,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable."
22945882,1,6,Premise,Claim,support,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
22945882,1,7,Premise,Claim,none,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking."
22945882,2,1,Premise,Premise,none,No significant improvement was observed in the placebo group (n = 10).,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).
22945882,2,3,Premise,Premise,none,No significant improvement was observed in the placebo group (n = 10).,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.
22945882,2,4,Premise,Premise,none,No significant improvement was observed in the placebo group (n = 10).,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,2,5,Premise,Premise,none,No significant improvement was observed in the placebo group (n = 10).,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable."
22945882,2,6,Premise,Claim,none,No significant improvement was observed in the placebo group (n = 10).,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
22945882,2,7,Premise,Claim,none,No significant improvement was observed in the placebo group (n = 10).,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking."
22945882,3,1,Premise,Premise,none,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.,Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).
22945882,3,2,Premise,Premise,none,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.,No significant improvement was observed in the placebo group (n = 10).
22945882,3,4,Premise,Premise,none,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,3,5,Premise,Premise,none,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable."
22945882,3,6,Premise,Claim,none,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
22945882,3,7,Premise,Claim,support,Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking."
22945882,4,1,Premise,Premise,none,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.",Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).
22945882,4,2,Premise,Premise,none,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.",No significant improvement was observed in the placebo group (n = 10).
22945882,4,3,Premise,Premise,none,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.",Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.
22945882,4,5,Premise,Premise,none,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.","No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable."
22945882,4,6,Premise,Claim,none,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.","SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
22945882,4,7,Premise,Claim,support,"SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.","Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking."
22945882,5,1,Premise,Premise,none,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable.",Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).
22945882,5,2,Premise,Premise,none,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable.",No significant improvement was observed in the placebo group (n = 10).
22945882,5,3,Premise,Premise,none,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable.",Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.
22945882,5,4,Premise,Premise,none,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable.","SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,5,6,Premise,Claim,support,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable.","SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
22945882,5,7,Premise,Claim,none,"No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable.","Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking."
22945882,6,1,Claim,Premise,none,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.",Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).
22945882,6,2,Claim,Premise,none,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.",No significant improvement was observed in the placebo group (n = 10).
22945882,6,3,Claim,Premise,none,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.",Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.
22945882,6,4,Claim,Premise,none,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.","SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,6,5,Claim,Premise,none,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.","No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable."
22945882,6,7,Claim,Claim,none,"SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.","Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking."
22945882,7,1,Claim,Premise,none,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking.",Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL (n = 20).
22945882,7,2,Claim,Premise,none,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking.",No significant improvement was observed in the placebo group (n = 10).
22945882,7,3,Claim,Premise,none,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking.",Pain reduction was significant from day 4 till end of treatment with SAMITAL and from days 7 to 21 in placebo patients.
22945882,7,4,Claim,Premise,none,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking.","SAMITAL also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,7,5,Claim,Premise,none,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking.","No severe adverse events were observed with SAMITAL, and systemic absorption of relevant active ingredients was undetectable."
22945882,7,6,Claim,Claim,none,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL on activities like drinking, eating and speaking.","SAMITAL significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
23017512,1,2,Premise,Premise,none,"At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001).","At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively."
23017512,1,3,Premise,Premise,none,"At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001).","We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points."
23017512,1,4,Premise,Premise,none,"At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001).","No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65)."
23017512,1,5,Premise,Claim,support,"At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001).","In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins."
23017512,2,1,Premise,Premise,none,"At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively.","At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001)."
23017512,2,3,Premise,Premise,none,"At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively.","We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points."
23017512,2,4,Premise,Premise,none,"At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively.","No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65)."
23017512,2,5,Premise,Claim,support,"At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively.","In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins."
23017512,3,1,Premise,Premise,none,"We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points.","At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001)."
23017512,3,2,Premise,Premise,none,"We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points.","At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively."
23017512,3,4,Premise,Premise,none,"We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points.","No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65)."
23017512,3,5,Premise,Claim,support,"We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points.","In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins."
23017512,4,1,Premise,Premise,none,"No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65).","At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001)."
23017512,4,2,Premise,Premise,none,"No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65).","At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively."
23017512,4,3,Premise,Premise,none,"No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65).","We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points."
23017512,4,5,Premise,Claim,none,"No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65).","In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins."
23017512,5,1,Claim,Premise,none,"In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins.","At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001)."
23017512,5,2,Claim,Premise,none,"In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins.","At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively."
23017512,5,3,Claim,Premise,none,"In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins.","We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points."
23017512,5,4,Claim,Premise,none,"In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins.","No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65)."
23294853,1,2,Premise,Premise,none,"The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (56 months, 95% CI 50-62 vs 49 months, 45-54; hazard ratio 13, 95% CI 11-16, p=0014).","Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%])."
23294853,1,3,Premise,Premise,none,"The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (56 months, 95% CI 50-62 vs 49 months, 45-54; hazard ratio 13, 95% CI 11-16, p=0014).","Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0002)."
23294853,1,4,Premise,Claim,support,"The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (56 months, 95% CI 50-62 vs 49 months, 45-54; hazard ratio 13, 95% CI 11-16, p=0014).",Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.
23294853,2,1,Premise,Premise,none,"Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%]).","The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (56 months, 95% CI 50-62 vs 49 months, 45-54; hazard ratio 13, 95% CI 11-16, p=0014)."
23294853,2,3,Premise,Premise,none,"Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%]).","Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0002)."
23294853,2,4,Premise,Claim,support,"Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%]).",Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.
23294853,3,1,Premise,Premise,none,"Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0002).","The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (56 months, 95% CI 50-62 vs 49 months, 45-54; hazard ratio 13, 95% CI 11-16, p=0014)."
23294853,3,2,Premise,Premise,none,"Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0002).","Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%])."
23294853,3,4,Premise,Claim,support,"Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0002).",Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.
23294853,4,1,Claim,Premise,none,Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.,"The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (56 months, 95% CI 50-62 vs 49 months, 45-54; hazard ratio 13, 95% CI 11-16, p=0014)."
23294853,4,2,Claim,Premise,none,Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.,"Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%])."
23294853,4,3,Claim,Premise,none,Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated.,"Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0002)."
11821453,1,2,Premise,Premise,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.","Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,1,3,Premise,Premise,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.","The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,1,4,Premise,Premise,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.","The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,1,5,Premise,Premise,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.",Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,1,6,Premise,Premise,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.","The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,1,7,Premise,Premise,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.",Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,1,8,Premise,Claim,none,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.","There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,1,9,Premise,Claim,support,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.",Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,2,1,Premise,Premise,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.","The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,2,3,Premise,Premise,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.","The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,2,4,Premise,Premise,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.","The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,2,5,Premise,Premise,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.",Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,2,6,Premise,Premise,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.","The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,2,7,Premise,Premise,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.",Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,2,8,Premise,Claim,none,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.","There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,2,9,Premise,Claim,support,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively.",Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,3,1,Premise,Premise,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.","The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,3,2,Premise,Premise,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.","Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,3,4,Premise,Premise,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.","The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,3,5,Premise,Premise,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.",Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,3,6,Premise,Premise,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.","The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,3,7,Premise,Premise,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.",Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,3,8,Premise,Claim,none,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.","There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,3,9,Premise,Claim,support,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively.",Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,4,1,Premise,Premise,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.","The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,4,2,Premise,Premise,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.","Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,4,3,Premise,Premise,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.","The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,4,5,Premise,Premise,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.",Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,4,6,Premise,Premise,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.","The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,4,7,Premise,Premise,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.",Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,4,8,Premise,Claim,none,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.","There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,4,9,Premise,Claim,support,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively.",Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,5,1,Premise,Premise,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,5,2,Premise,Premise,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,5,3,Premise,Premise,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,5,4,Premise,Premise,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,5,6,Premise,Premise,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,5,7,Premise,Premise,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,5,8,Premise,Claim,none,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,5,9,Premise,Claim,support,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,6,1,Premise,Premise,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).","The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,6,2,Premise,Premise,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).","Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,6,3,Premise,Premise,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).","The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,6,4,Premise,Premise,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).","The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,6,5,Premise,Premise,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).",Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,6,7,Premise,Premise,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).",Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,6,8,Premise,Claim,none,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).","There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,6,9,Premise,Claim,support,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).",Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,7,1,Premise,Premise,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,7,2,Premise,Premise,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,7,3,Premise,Premise,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,7,4,Premise,Premise,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,7,5,Premise,Premise,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,7,6,Premise,Premise,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,7,8,Premise,Claim,none,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,7,9,Premise,Claim,support,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,8,1,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.","The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,8,2,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.","Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,8,3,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.","The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,8,4,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.","The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,8,5,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.",Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,8,6,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.","The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,8,7,Claim,Premise,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.",Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,8,9,Claim,Claim,none,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events.",Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
11821453,9,1,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,9,2,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,9,3,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,9,4,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,9,5,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later.
11821453,9,6,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,9,7,Claim,Premise,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab.
11821453,9,8,Claim,Claim,none,Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
23545101,1,2,MajorClaim,Premise,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,"Treatment was well tolerated in both groups,"
23545101,1,3,MajorClaim,Premise,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,1,4,MajorClaim,Premise,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,1,5,MajorClaim,Premise,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,1,6,MajorClaim,Premise,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,1,7,MajorClaim,Claim,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
23545101,1,8,MajorClaim,Claim,none,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.,our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,2,1,Premise,MajorClaim,none,"Treatment was well tolerated in both groups,",Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,2,3,Premise,Premise,none,"Treatment was well tolerated in both groups,",although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,2,4,Premise,Premise,none,"Treatment was well tolerated in both groups,",Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,2,5,Premise,Premise,none,"Treatment was well tolerated in both groups,","No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,2,6,Premise,Premise,none,"Treatment was well tolerated in both groups,",No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,2,7,Premise,Claim,attack,"Treatment was well tolerated in both groups,","a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
23545101,2,8,Premise,Claim,none,"Treatment was well tolerated in both groups,",our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,3,1,Premise,MajorClaim,none,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,3,2,Premise,Premise,attack,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,"Treatment was well tolerated in both groups,"
23545101,3,4,Premise,Premise,none,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,3,5,Premise,Premise,none,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,3,6,Premise,Premise,none,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,3,7,Premise,Claim,none,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
23545101,3,8,Premise,Claim,none,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.,our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,4,1,Premise,MajorClaim,none,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,4,2,Premise,Premise,none,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,"Treatment was well tolerated in both groups,"
23545101,4,3,Premise,Premise,none,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,4,5,Premise,Premise,none,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,4,6,Premise,Premise,none,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,4,7,Premise,Claim,none,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
23545101,4,8,Premise,Claim,support,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.,our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,5,1,Premise,MajorClaim,none,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).",Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,5,2,Premise,Premise,none,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).","Treatment was well tolerated in both groups,"
23545101,5,3,Premise,Premise,none,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).",although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,5,4,Premise,Premise,none,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).",Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,5,6,Premise,Premise,none,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).",No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,5,7,Premise,Claim,none,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).","a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
23545101,5,8,Premise,Claim,support,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002).",our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,6,1,Premise,MajorClaim,none,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,6,2,Premise,Premise,none,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,"Treatment was well tolerated in both groups,"
23545101,6,3,Premise,Premise,none,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,6,4,Premise,Premise,none,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,6,5,Premise,Premise,none,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,6,7,Premise,Claim,none,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
23545101,6,8,Premise,Claim,support,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.,our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,7,1,Claim,MajorClaim,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,",Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,7,2,Claim,Premise,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,","Treatment was well tolerated in both groups,"
23545101,7,3,Claim,Premise,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,",although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,7,4,Claim,Premise,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,",Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,7,5,Claim,Premise,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,","No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,7,6,Claim,Premise,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,",No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,7,8,Claim,Claim,none,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,",our study failed to show significant differences between the 2 drugs in terms of quality of life.
23545101,8,1,Claim,MajorClaim,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,Bacillus Calmette-Gurin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer.
23545101,8,2,Claim,Premise,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,"Treatment was well tolerated in both groups,"
23545101,8,3,Claim,Premise,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,although local and systemic side effects were more frequently reported in the bacillus Calmette-Gurin arm.
23545101,8,4,Claim,Premise,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions.
23545101,8,5,Claim,Premise,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Gurin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,8,6,Claim,Premise,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup.
23545101,8,7,Claim,Claim,none,our study failed to show significant differences between the 2 drugs in terms of quality of life.,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Gurin compared to gemcitabine,"
17664467,1,2,MajorClaim,Premise,none,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009)."
17664467,1,3,MajorClaim,Premise,none,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,"
17664467,1,4,MajorClaim,Premise,none,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.,the results were not statistically significant.
17664467,1,5,MajorClaim,Premise,none,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.,Pain-free survival and time to first cancer pain-related opioid intake were comparable.
17664467,1,6,MajorClaim,Claim,none,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF."
17664467,2,1,Premise,MajorClaim,none,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009).",For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.
17664467,2,3,Premise,Premise,none,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009).","Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,"
17664467,2,4,Premise,Premise,none,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009).",the results were not statistically significant.
17664467,2,5,Premise,Premise,none,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009).",Pain-free survival and time to first cancer pain-related opioid intake were comparable.
17664467,2,6,Premise,Claim,support,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009).","The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF."
17664467,3,1,Premise,MajorClaim,none,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,",For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.
17664467,3,2,Premise,Premise,attack,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,","DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009)."
17664467,3,4,Premise,Premise,none,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,",the results were not statistically significant.
17664467,3,5,Premise,Premise,none,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,",Pain-free survival and time to first cancer pain-related opioid intake were comparable.
17664467,3,6,Premise,Claim,none,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,","The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF."
17664467,4,1,Premise,MajorClaim,none,the results were not statistically significant.,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.
17664467,4,2,Premise,Premise,none,the results were not statistically significant.,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009)."
17664467,4,3,Premise,Premise,attack,the results were not statistically significant.,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,"
17664467,4,5,Premise,Premise,none,the results were not statistically significant.,Pain-free survival and time to first cancer pain-related opioid intake were comparable.
17664467,4,6,Premise,Claim,none,the results were not statistically significant.,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF."
17664467,5,1,Premise,MajorClaim,none,Pain-free survival and time to first cancer pain-related opioid intake were comparable.,For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.
17664467,5,2,Premise,Premise,none,Pain-free survival and time to first cancer pain-related opioid intake were comparable.,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009)."
17664467,5,3,Premise,Premise,none,Pain-free survival and time to first cancer pain-related opioid intake were comparable.,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,"
17664467,5,4,Premise,Premise,none,Pain-free survival and time to first cancer pain-related opioid intake were comparable.,the results were not statistically significant.
17664467,5,6,Premise,Claim,support,Pain-free survival and time to first cancer pain-related opioid intake were comparable.,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF."
17664467,6,1,Claim,MajorClaim,none,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF.",For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable.
17664467,6,2,Claim,Premise,none,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF.","DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009)."
17664467,6,3,Claim,Premise,none,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF.","Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,"
17664467,6,4,Claim,Premise,none,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF.",the results were not statistically significant.
17664467,6,5,Claim,Premise,none,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF.",Pain-free survival and time to first cancer pain-related opioid intake were comparable.
23657969,1,2,Premise,Claim,support,"Relative to the control group, women in the TSM group performed better on the verbal memory test (Rey Auditory Verbal Learning Test trial 1) (p=0.06) and the short-term memory and processing speed task (Digit Symbol) (p=0.09) and reported improved cognitive function (p=0.06), cognitive abilities (p=0.08), mental health (p=0.04), and spirituality (p=0.05) at the end of treatment but not 1month later.",This randomized controlled trial revealed that TSM program appears to be a feasible and acceptable intervention and may be associated with short-term improvements in objective and subjective cognitive function as well as mental health and spirituality in breast cancer patients.
23657969,2,1,Claim,Premise,none,This randomized controlled trial revealed that TSM program appears to be a feasible and acceptable intervention and may be associated with short-term improvements in objective and subjective cognitive function as well as mental health and spirituality in breast cancer patients.,"Relative to the control group, women in the TSM group performed better on the verbal memory test (Rey Auditory Verbal Learning Test trial 1) (p=0.06) and the short-term memory and processing speed task (Digit Symbol) (p=0.09) and reported improved cognitive function (p=0.06), cognitive abilities (p=0.08), mental health (p=0.04), and spirituality (p=0.05) at the end of treatment but not 1month later."
23696477,1,2,Premise,Premise,none,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001).","The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),"
23696477,1,3,Premise,Premise,none,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001).","but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987)."
23696477,1,4,Premise,Premise,none,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001).",QoL over 28 days was significantly better in the ERP group (P = 0002).
23696477,1,5,Premise,Premise,none,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001).",There was no difference in patient satisfaction.
23696477,1,6,Premise,Claim,none,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001).",ERPs for open liver resection surgery are safe and effective.
23696477,1,7,Premise,Claim,support,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001).","Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
23696477,2,1,Premise,Premise,none,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),","Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001)."
23696477,2,3,Premise,Premise,none,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),","but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987)."
23696477,2,4,Premise,Premise,none,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),",QoL over 28 days was significantly better in the ERP group (P = 0002).
23696477,2,5,Premise,Premise,none,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),",There was no difference in patient satisfaction.
23696477,2,6,Premise,Claim,support,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),",ERPs for open liver resection surgery are safe and effective.
23696477,2,7,Premise,Claim,none,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),","Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
23696477,3,1,Premise,Premise,none,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987).","Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001)."
23696477,3,2,Premise,Premise,attack,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987).","The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),"
23696477,3,4,Premise,Premise,none,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987).",QoL over 28 days was significantly better in the ERP group (P = 0002).
23696477,3,5,Premise,Premise,none,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987).",There was no difference in patient satisfaction.
23696477,3,6,Premise,Claim,none,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987).",ERPs for open liver resection surgery are safe and effective.
23696477,3,7,Premise,Claim,none,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987).","Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
23696477,4,1,Premise,Premise,none,QoL over 28 days was significantly better in the ERP group (P = 0002).,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001)."
23696477,4,2,Premise,Premise,none,QoL over 28 days was significantly better in the ERP group (P = 0002).,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),"
23696477,4,3,Premise,Premise,none,QoL over 28 days was significantly better in the ERP group (P = 0002).,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987)."
23696477,4,5,Premise,Premise,none,QoL over 28 days was significantly better in the ERP group (P = 0002).,There was no difference in patient satisfaction.
23696477,4,6,Premise,Claim,none,QoL over 28 days was significantly better in the ERP group (P = 0002).,ERPs for open liver resection surgery are safe and effective.
23696477,4,7,Premise,Claim,support,QoL over 28 days was significantly better in the ERP group (P = 0002).,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
23696477,5,1,Premise,Premise,none,There was no difference in patient satisfaction.,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001)."
23696477,5,2,Premise,Premise,none,There was no difference in patient satisfaction.,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),"
23696477,5,3,Premise,Premise,none,There was no difference in patient satisfaction.,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987)."
23696477,5,4,Premise,Premise,none,There was no difference in patient satisfaction.,QoL over 28 days was significantly better in the ERP group (P = 0002).
23696477,5,6,Premise,Claim,none,There was no difference in patient satisfaction.,ERPs for open liver resection surgery are safe and effective.
23696477,5,7,Premise,Claim,none,There was no difference in patient satisfaction.,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
23696477,6,1,Claim,Premise,none,ERPs for open liver resection surgery are safe and effective.,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001)."
23696477,6,2,Claim,Premise,none,ERPs for open liver resection surgery are safe and effective.,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),"
23696477,6,3,Claim,Premise,none,ERPs for open liver resection surgery are safe and effective.,"but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987)."
23696477,6,4,Claim,Premise,none,ERPs for open liver resection surgery are safe and effective.,QoL over 28 days was significantly better in the ERP group (P = 0002).
23696477,6,5,Claim,Premise,none,ERPs for open liver resection surgery are safe and effective.,There was no difference in patient satisfaction.
23696477,6,7,Claim,Claim,none,ERPs for open liver resection surgery are safe and effective.,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
23696477,7,1,Claim,Premise,none,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL.","Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0001), as was LOS (4 days versus 7 days; P < 0001)."
23696477,7,2,Claim,Premise,none,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL.","The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0020),"
23696477,7,3,Claim,Premise,none,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL.","but not surgical complications (15 versus 11 per cent; P = 0612), readmissions (4 versus 0 per cent; P = 0153) or mortality (both 2 per cent; P = 0987)."
23696477,7,4,Claim,Premise,none,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL.",QoL over 28 days was significantly better in the ERP group (P = 0002).
23696477,7,5,Claim,Premise,none,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL.",There was no difference in patient satisfaction.
23696477,7,6,Claim,Claim,none,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL.",ERPs for open liver resection surgery are safe and effective.
10811675,1,2,Premise,Premise,none,"Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047).","The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003)."
10811675,1,3,Premise,Premise,none,"Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047).","Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2)."
10811675,1,4,Premise,Premise,none,"Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047).","Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups."
10811675,1,5,Premise,Claim,support,"Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047).","Treatment with docetaxel is associated with significant prolongation of survival,"
10811675,1,6,Premise,Claim,none,"Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047).","at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks."
10811675,2,1,Premise,Premise,none,"The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003).","Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047)."
10811675,2,3,Premise,Premise,none,"The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003).","Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2)."
10811675,2,4,Premise,Premise,none,"The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003).","Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups."
10811675,2,5,Premise,Claim,none,"The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003).","Treatment with docetaxel is associated with significant prolongation of survival,"
10811675,2,6,Premise,Claim,support,"The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003).","at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks."
10811675,3,1,Premise,Premise,none,"Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2).","Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047)."
10811675,3,2,Premise,Premise,none,"Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2).","The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003)."
10811675,3,4,Premise,Premise,none,"Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2).","Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups."
10811675,3,5,Premise,Claim,none,"Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2).","Treatment with docetaxel is associated with significant prolongation of survival,"
10811675,3,6,Premise,Claim,support,"Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2).","at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks."
10811675,4,1,Premise,Premise,none,"Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups.","Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047)."
10811675,4,2,Premise,Premise,none,"Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups.","The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003)."
10811675,4,3,Premise,Premise,none,"Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups.","Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2)."
10811675,4,5,Premise,Claim,none,"Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups.","Treatment with docetaxel is associated with significant prolongation of survival,"
10811675,4,6,Premise,Claim,none,"Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups.","at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks."
10811675,5,1,Claim,Premise,none,"Treatment with docetaxel is associated with significant prolongation of survival,","Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047)."
10811675,5,2,Claim,Premise,none,"Treatment with docetaxel is associated with significant prolongation of survival,","The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003)."
10811675,5,3,Claim,Premise,none,"Treatment with docetaxel is associated with significant prolongation of survival,","Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2)."
10811675,5,4,Claim,Premise,none,"Treatment with docetaxel is associated with significant prolongation of survival,","Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups."
10811675,5,6,Claim,Claim,none,"Treatment with docetaxel is associated with significant prolongation of survival,","at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks."
10811675,6,1,Claim,Premise,none,"at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.","Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047)."
10811675,6,2,Claim,Premise,none,"at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.","The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003)."
10811675,6,3,Claim,Premise,none,"at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.","Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2)."
10811675,6,4,Claim,Premise,none,"at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.","Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups."
10811675,6,5,Claim,Claim,none,"at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks.","Treatment with docetaxel is associated with significant prolongation of survival,"
11786563,1,2,Claim,Premise,none,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life.","No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001)."
11786563,1,3,Claim,Premise,none,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life.",Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).
11786563,1,4,Claim,Premise,none,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life.",No significant differences in REE between the ATP and control groups were observed.
11786563,1,5,Claim,Claim,none,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life.",The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.
11786563,1,6,Claim,Premise,none,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life.",These effects are partly ascribed to maintenance of energy intake.
11786563,2,1,Premise,Claim,support,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001).","In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life."
11786563,2,3,Premise,Premise,none,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001).",Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).
11786563,2,4,Premise,Premise,none,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001).",No significant differences in REE between the ATP and control groups were observed.
11786563,2,5,Premise,Claim,none,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001).",The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.
11786563,2,6,Premise,Premise,none,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001).",These effects are partly ascribed to maintenance of energy intake.
11786563,3,1,Premise,Claim,support,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life."
11786563,3,2,Premise,Premise,none,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001)."
11786563,3,4,Premise,Premise,none,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).,No significant differences in REE between the ATP and control groups were observed.
11786563,3,5,Premise,Claim,none,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.
11786563,3,6,Premise,Premise,none,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).,These effects are partly ascribed to maintenance of energy intake.
11786563,4,1,Premise,Claim,none,No significant differences in REE between the ATP and control groups were observed.,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life."
11786563,4,2,Premise,Premise,none,No significant differences in REE between the ATP and control groups were observed.,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001)."
11786563,4,3,Premise,Premise,none,No significant differences in REE between the ATP and control groups were observed.,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).
11786563,4,5,Premise,Claim,none,No significant differences in REE between the ATP and control groups were observed.,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.
11786563,4,6,Premise,Premise,none,No significant differences in REE between the ATP and control groups were observed.,These effects are partly ascribed to maintenance of energy intake.
11786563,5,1,Claim,Claim,none,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life."
11786563,5,2,Claim,Premise,none,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001)."
11786563,5,3,Claim,Premise,none,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).
11786563,5,4,Claim,Premise,none,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.,No significant differences in REE between the ATP and control groups were observed.
11786563,5,6,Claim,Premise,none,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.,These effects are partly ascribed to maintenance of energy intake.
11786563,6,1,Premise,Claim,none,These effects are partly ascribed to maintenance of energy intake.,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life."
11786563,6,2,Premise,Premise,none,These effects are partly ascribed to maintenance of energy intake.,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001)."
11786563,6,3,Premise,Premise,none,These effects are partly ascribed to maintenance of energy intake.,Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004).
11786563,6,4,Premise,Premise,none,These effects are partly ascribed to maintenance of energy intake.,No significant differences in REE between the ATP and control groups were observed.
11786563,6,5,Premise,Claim,none,These effects are partly ascribed to maintenance of energy intake.,The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues.
16476841,1,2,Premise,Premise,none,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,1,3,Premise,Premise,none,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,1,4,Premise,Premise,none,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.,"QOL declined in patients receiving BSC,"
16476841,1,5,Premise,Premise,none,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,1,6,Premise,Claim,support,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
16476841,1,7,Premise,Claim,none,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.,This study supports the positive effects of early intervention when analyzed according to initial Hb value.
16476841,2,1,Premise,Premise,none,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.",Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
16476841,2,3,Premise,Premise,none,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.","For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,2,4,Premise,Premise,none,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.","QOL declined in patients receiving BSC,"
16476841,2,5,Premise,Premise,none,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.","the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,2,6,Premise,Claim,support,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.","In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
16476841,2,7,Premise,Claim,none,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.",This study supports the positive effects of early intervention when analyzed according to initial Hb value.
16476841,3,1,Premise,Premise,none,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.",Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
16476841,3,2,Premise,Premise,none,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.","EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,3,4,Premise,Premise,none,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.","QOL declined in patients receiving BSC,"
16476841,3,5,Premise,Premise,none,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.","the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,3,6,Premise,Claim,none,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.","In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
16476841,3,7,Premise,Claim,none,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.",This study supports the positive effects of early intervention when analyzed according to initial Hb value.
16476841,4,1,Premise,Premise,none,"QOL declined in patients receiving BSC,",Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
16476841,4,2,Premise,Premise,none,"QOL declined in patients receiving BSC,","EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,4,3,Premise,Premise,none,"QOL declined in patients receiving BSC,","For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,4,5,Premise,Premise,none,"QOL declined in patients receiving BSC,","the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,4,6,Premise,Claim,none,"QOL declined in patients receiving BSC,","In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
16476841,4,7,Premise,Claim,none,"QOL declined in patients receiving BSC,",This study supports the positive effects of early intervention when analyzed according to initial Hb value.
16476841,5,1,Premise,Premise,none,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.",Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
16476841,5,2,Premise,Premise,none,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.","EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,5,3,Premise,Premise,none,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.","For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,5,4,Premise,Premise,none,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.","QOL declined in patients receiving BSC,"
16476841,5,6,Premise,Claim,support,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.","In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
16476841,5,7,Premise,Claim,none,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.",This study supports the positive effects of early intervention when analyzed according to initial Hb value.
16476841,6,1,Claim,Premise,none,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.",Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
16476841,6,2,Claim,Premise,none,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.","EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,6,3,Claim,Premise,none,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.","For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,6,4,Claim,Premise,none,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.","QOL declined in patients receiving BSC,"
16476841,6,5,Claim,Premise,none,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.","the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,6,7,Claim,Claim,support,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.",This study supports the positive effects of early intervention when analyzed according to initial Hb value.
16476841,7,1,Claim,Premise,none,This study supports the positive effects of early intervention when analyzed according to initial Hb value.,Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
16476841,7,2,Claim,Premise,none,This study supports the positive effects of early intervention when analyzed according to initial Hb value.,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,7,3,Claim,Premise,none,This study supports the positive effects of early intervention when analyzed according to initial Hb value.,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,7,4,Claim,Premise,none,This study supports the positive effects of early intervention when analyzed according to initial Hb value.,"QOL declined in patients receiving BSC,"
16476841,7,5,Claim,Premise,none,This study supports the positive effects of early intervention when analyzed according to initial Hb value.,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,7,6,Claim,Claim,none,This study supports the positive effects of early intervention when analyzed according to initial Hb value.,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
23686277,1,2,Premise,Premise,none,The trial had to be stopped prematurely due to insufficient patient recruitment.,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml."
23686277,1,3,Premise,Claim,attack,The trial had to be stopped prematurely due to insufficient patient recruitment.,Laparoscopic surgery was superior regarding the length of skin incision;
23686277,1,4,Premise,Claim,attack,The trial had to be stopped prematurely due to insufficient patient recruitment.,the conventional approach was superior in duration of operation.
23686277,1,5,Premise,Premise,none,The trial had to be stopped prematurely due to insufficient patient recruitment.,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,1,6,Premise,Claim,attack,The trial had to be stopped prematurely due to insufficient patient recruitment.,There was no difference with respect to blood loss between the LAP and the CON group.
23686277,1,7,Premise,Claim,attack,The trial had to be stopped prematurely due to insufficient patient recruitment.,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23686277,2,1,Premise,Premise,none,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml.",The trial had to be stopped prematurely due to insufficient patient recruitment.
23686277,2,3,Premise,Claim,none,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml.",Laparoscopic surgery was superior regarding the length of skin incision;
23686277,2,4,Premise,Claim,none,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml.",the conventional approach was superior in duration of operation.
23686277,2,5,Premise,Premise,none,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml.","There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,2,6,Premise,Claim,support,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml.",There was no difference with respect to blood loss between the LAP and the CON group.
23686277,2,7,Premise,Claim,none,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml.","The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23686277,3,1,Claim,Premise,none,Laparoscopic surgery was superior regarding the length of skin incision;,The trial had to be stopped prematurely due to insufficient patient recruitment.
23686277,3,2,Claim,Premise,none,Laparoscopic surgery was superior regarding the length of skin incision;,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml."
23686277,3,4,Claim,Claim,none,Laparoscopic surgery was superior regarding the length of skin incision;,the conventional approach was superior in duration of operation.
23686277,3,5,Claim,Premise,none,Laparoscopic surgery was superior regarding the length of skin incision;,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,3,6,Claim,Claim,none,Laparoscopic surgery was superior regarding the length of skin incision;,There was no difference with respect to blood loss between the LAP and the CON group.
23686277,3,7,Claim,Claim,none,Laparoscopic surgery was superior regarding the length of skin incision;,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23686277,4,1,Claim,Premise,none,the conventional approach was superior in duration of operation.,The trial had to be stopped prematurely due to insufficient patient recruitment.
23686277,4,2,Claim,Premise,none,the conventional approach was superior in duration of operation.,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml."
23686277,4,3,Claim,Claim,none,the conventional approach was superior in duration of operation.,Laparoscopic surgery was superior regarding the length of skin incision;
23686277,4,5,Claim,Premise,none,the conventional approach was superior in duration of operation.,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,4,6,Claim,Claim,none,the conventional approach was superior in duration of operation.,There was no difference with respect to blood loss between the LAP and the CON group.
23686277,4,7,Claim,Claim,none,the conventional approach was superior in duration of operation.,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23686277,5,1,Premise,Premise,none,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches.",The trial had to be stopped prematurely due to insufficient patient recruitment.
23686277,5,2,Premise,Premise,none,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches.","There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml."
23686277,5,3,Premise,Claim,none,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches.",Laparoscopic surgery was superior regarding the length of skin incision;
23686277,5,4,Premise,Claim,none,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches.",the conventional approach was superior in duration of operation.
23686277,5,6,Premise,Claim,none,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches.",There was no difference with respect to blood loss between the LAP and the CON group.
23686277,5,7,Premise,Claim,support,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches.","The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23686277,6,1,Claim,Premise,none,There was no difference with respect to blood loss between the LAP and the CON group.,The trial had to be stopped prematurely due to insufficient patient recruitment.
23686277,6,2,Claim,Premise,none,There was no difference with respect to blood loss between the LAP and the CON group.,"There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml."
23686277,6,3,Claim,Claim,none,There was no difference with respect to blood loss between the LAP and the CON group.,Laparoscopic surgery was superior regarding the length of skin incision;
23686277,6,4,Claim,Claim,none,There was no difference with respect to blood loss between the LAP and the CON group.,the conventional approach was superior in duration of operation.
23686277,6,5,Claim,Premise,none,There was no difference with respect to blood loss between the LAP and the CON group.,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,6,7,Claim,Claim,none,There was no difference with respect to blood loss between the LAP and the CON group.,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23686277,7,1,Claim,Premise,none,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery.",The trial had to be stopped prematurely due to insufficient patient recruitment.
23686277,7,2,Claim,Premise,none,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery.","There was no difference in the amount of blood loss between both groups: LAP 261.5195.4ml, CON 228.1119.5ml."
23686277,7,3,Claim,Claim,none,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery.",Laparoscopic surgery was superior regarding the length of skin incision;
23686277,7,4,Claim,Claim,none,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery.",the conventional approach was superior in duration of operation.
23686277,7,5,Claim,Premise,none,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery.","There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,7,6,Claim,Claim,none,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery.",There was no difference with respect to blood loss between the LAP and the CON group.
16476840,1,2,Premise,Premise,none,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.","This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC."
16476840,1,3,Premise,Premise,none,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.",A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
16476840,1,4,Premise,Premise,none,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.",Patients in this study had impaired QOL compared with population norms.
16476840,1,5,Premise,Claim,support,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.","Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
16476840,2,1,Premise,Premise,none,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.","Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale."
16476840,2,3,Premise,Premise,none,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.",A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
16476840,2,4,Premise,Premise,none,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.",Patients in this study had impaired QOL compared with population norms.
16476840,2,5,Premise,Claim,support,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.","Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
16476840,3,1,Premise,Premise,none,A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale."
16476840,3,2,Premise,Premise,none,A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC."
16476840,3,4,Premise,Premise,none,A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.,Patients in this study had impaired QOL compared with population norms.
16476840,3,5,Premise,Claim,support,A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
16476840,4,1,Premise,Premise,none,Patients in this study had impaired QOL compared with population norms.,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale."
16476840,4,2,Premise,Premise,none,Patients in this study had impaired QOL compared with population norms.,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC."
16476840,4,3,Premise,Premise,none,Patients in this study had impaired QOL compared with population norms.,A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
16476840,4,5,Premise,Claim,attack,Patients in this study had impaired QOL compared with population norms.,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
16476840,5,1,Claim,Premise,none,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.","Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale."
16476840,5,2,Claim,Premise,none,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.","This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC."
16476840,5,3,Claim,Premise,none,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.",A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
16476840,5,4,Claim,Premise,none,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.",Patients in this study had impaired QOL compared with population norms.
22097195,1,2,Premise,Premise,none,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063).",The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)
22097195,1,3,Premise,Premise,none,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063).","except cognitive and social functions, the symptoms of dysphagia and pain in other parts."
22097195,1,4,Premise,Claim,support,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063).",The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.
22097195,1,5,Premise,Claim,none,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063).",It was advantageous over improving the QOL.
22097195,1,6,Premise,Claim,none,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063).",It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.
22097195,2,1,Premise,Premise,none,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05),"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063)."
22097195,2,3,Premise,Premise,none,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05),"except cognitive and social functions, the symptoms of dysphagia and pain in other parts."
22097195,2,4,Premise,Claim,none,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05),The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.
22097195,2,5,Premise,Claim,support,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05),It was advantageous over improving the QOL.
22097195,2,6,Premise,Claim,none,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05),It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.
22097195,3,1,Premise,Premise,none,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts.","The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063)."
22097195,3,2,Premise,Premise,attack,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts.",The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)
22097195,3,4,Premise,Claim,none,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts.",The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.
22097195,3,5,Premise,Claim,none,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts.",It was advantageous over improving the QOL.
22097195,3,6,Premise,Claim,none,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts.",It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.
22097195,4,1,Claim,Premise,none,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063)."
22097195,4,2,Claim,Premise,none,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)
22097195,4,3,Claim,Premise,none,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts."
22097195,4,5,Claim,Claim,none,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.,It was advantageous over improving the QOL.
22097195,4,6,Claim,Claim,none,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.
22097195,5,1,Claim,Premise,none,It was advantageous over improving the QOL.,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063)."
22097195,5,2,Claim,Premise,none,It was advantageous over improving the QOL.,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)
22097195,5,3,Claim,Premise,none,It was advantageous over improving the QOL.,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts."
22097195,5,4,Claim,Claim,none,It was advantageous over improving the QOL.,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.
22097195,5,6,Claim,Claim,none,It was advantageous over improving the QOL.,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.
22097195,6,1,Claim,Premise,none,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063)."
22097195,6,2,Claim,Premise,none,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.,The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)
22097195,6,3,Claim,Premise,none,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts."
22097195,6,4,Claim,Claim,support,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.,The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.
22097195,6,5,Claim,Claim,none,It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.,It was advantageous over improving the QOL.
9143576,1,2,MajorClaim,Premise,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,1,3,MajorClaim,Premise,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,1,4,MajorClaim,Premise,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,whereas their mental well-being improved after surgery.
9143576,1,5,MajorClaim,Premise,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,1,6,MajorClaim,Premise,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,1,7,MajorClaim,Claim,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,1,8,MajorClaim,Claim,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,"A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,1,9,MajorClaim,Claim,none,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,2,1,Premise,MajorClaim,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.",The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,2,3,Premise,Premise,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.","Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,2,4,Premise,Premise,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.",whereas their mental well-being improved after surgery.
9143576,2,5,Premise,Premise,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.","Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,2,6,Premise,Premise,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.",Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,2,7,Premise,Claim,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.","We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,2,8,Premise,Claim,support,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.","A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,2,9,Premise,Claim,none,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded.",a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,3,1,Premise,MajorClaim,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,",The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,3,2,Premise,Premise,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,","The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,3,4,Premise,Premise,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,",whereas their mental well-being improved after surgery.
9143576,3,5,Premise,Premise,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,","Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,3,6,Premise,Premise,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,",Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,3,7,Premise,Claim,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,","We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,3,8,Premise,Claim,support,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,","A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,3,9,Premise,Claim,none,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,",a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,4,1,Premise,MajorClaim,none,whereas their mental well-being improved after surgery.,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,4,2,Premise,Premise,none,whereas their mental well-being improved after surgery.,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,4,3,Premise,Premise,none,whereas their mental well-being improved after surgery.,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,4,5,Premise,Premise,none,whereas their mental well-being improved after surgery.,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,4,6,Premise,Premise,none,whereas their mental well-being improved after surgery.,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,4,7,Premise,Claim,support,whereas their mental well-being improved after surgery.,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,4,8,Premise,Claim,none,whereas their mental well-being improved after surgery.,"A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,4,9,Premise,Claim,none,whereas their mental well-being improved after surgery.,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,5,1,Premise,MajorClaim,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.",The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,5,2,Premise,Premise,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.","The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,5,3,Premise,Premise,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.","Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,5,4,Premise,Premise,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.",whereas their mental well-being improved after surgery.
9143576,5,6,Premise,Premise,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.",Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,5,7,Premise,Claim,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.","We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,5,8,Premise,Claim,none,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.","A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,5,9,Premise,Claim,support,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea.",a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,6,1,Premise,MajorClaim,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,6,2,Premise,Premise,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,6,3,Premise,Premise,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,6,4,Premise,Premise,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,whereas their mental well-being improved after surgery.
9143576,6,5,Premise,Premise,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,6,7,Premise,Claim,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,6,8,Premise,Claim,support,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,"A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,6,9,Premise,Claim,none,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,7,1,Claim,MajorClaim,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.",The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,7,2,Claim,Premise,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.","The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,7,3,Claim,Premise,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.","Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,7,4,Claim,Premise,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.",whereas their mental well-being improved after surgery.
9143576,7,5,Claim,Premise,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.","Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,7,6,Claim,Premise,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.",Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,7,8,Claim,Claim,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.","A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,7,9,Claim,Claim,none,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status.",a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,8,1,Claim,MajorClaim,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,",The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,8,2,Claim,Premise,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,","The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,8,3,Claim,Premise,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,","Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,8,4,Claim,Premise,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,",whereas their mental well-being improved after surgery.
9143576,8,5,Claim,Premise,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,","Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,8,6,Claim,Premise,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,",Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,8,7,Claim,Claim,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,","We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,8,9,Claim,Claim,none,"A pouch reconstruction after total gastrectomy does not improve quality of life,",a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.
9143576,9,1,Claim,MajorClaim,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy.
9143576,9,2,Claim,Premise,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,9,3,Claim,Premise,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,9,4,Claim,Premise,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,whereas their mental well-being improved after surgery.
9143576,9,5,Claim,Premise,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,9,6,Claim,Premise,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy.
9143576,9,7,Claim,Claim,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,9,8,Claim,Claim,none,a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible.,"A pouch reconstruction after total gastrectomy does not improve quality of life,"
23690410,1,2,Premise,Premise,none,"At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016).",A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months.
23690410,1,3,Premise,Premise,none,"At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016).","No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking."
23690410,1,4,Premise,Claim,support,"At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016).","The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors."
23690410,2,1,Premise,Premise,none,A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months.,"At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016)."
23690410,2,3,Premise,Premise,none,A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months.,"No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking."
23690410,2,4,Premise,Claim,support,A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months.,"The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors."
23690410,3,1,Premise,Premise,none,"No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking.","At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016)."
23690410,3,2,Premise,Premise,none,"No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking.",A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months.
23690410,3,4,Premise,Claim,none,"No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking.","The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors."
23690410,4,1,Claim,Premise,none,"The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors.","At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016)."
23690410,4,2,Claim,Premise,none,"The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors.",A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months.
23690410,4,3,Claim,Premise,none,"The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors.","No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking."
24084921,1,2,Premise,Premise,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,1,3,Premise,Premise,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","Most risks and benefits dissipated postintervention,"
24084921,1,4,Premise,Premise,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,1,5,Premise,Premise,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,1,6,Premise,Premise,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,1,7,Premise,Premise,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,1,8,Premise,Claim,support,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,1,9,Premise,Claim,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,1,10,Premise,Claim,none,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).",although it is appropriate for symptom management in some women.
24084921,2,1,Premise,Premise,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,2,3,Premise,Premise,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","Most risks and benefits dissipated postintervention,"
24084921,2,4,Premise,Premise,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,2,5,Premise,Premise,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,2,6,Premise,Premise,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,2,7,Premise,Premise,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,2,8,Premise,Claim,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,2,9,Premise,Claim,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,2,10,Premise,Claim,none,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.",although it is appropriate for symptom management in some women.
24084921,3,1,Premise,Premise,none,"Most risks and benefits dissipated postintervention,","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,3,2,Premise,Premise,attack,"Most risks and benefits dissipated postintervention,","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,3,4,Premise,Premise,none,"Most risks and benefits dissipated postintervention,","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,3,5,Premise,Premise,none,"Most risks and benefits dissipated postintervention,","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,3,6,Premise,Premise,none,"Most risks and benefits dissipated postintervention,","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,3,7,Premise,Premise,none,"Most risks and benefits dissipated postintervention,","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,3,8,Premise,Claim,none,"Most risks and benefits dissipated postintervention,",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,3,9,Premise,Claim,none,"Most risks and benefits dissipated postintervention,","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,3,10,Premise,Claim,none,"Most risks and benefits dissipated postintervention,",although it is appropriate for symptom management in some women.
24084921,4,1,Premise,Premise,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,4,2,Premise,Premise,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,4,3,Premise,Premise,attack,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","Most risks and benefits dissipated postintervention,"
24084921,4,5,Premise,Premise,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,4,6,Premise,Premise,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,4,7,Premise,Premise,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,4,8,Premise,Claim,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,4,9,Premise,Claim,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,4,10,Premise,Claim,none,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).",although it is appropriate for symptom management in some women.
24084921,5,1,Premise,Premise,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,5,2,Premise,Premise,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,5,3,Premise,Premise,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","Most risks and benefits dissipated postintervention,"
24084921,5,4,Premise,Premise,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,5,6,Premise,Premise,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,5,7,Premise,Premise,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,5,8,Premise,Claim,support,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,5,9,Premise,Claim,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,5,10,Premise,Claim,none,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).",although it is appropriate for symptom management in some women.
24084921,6,1,Premise,Premise,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,6,2,Premise,Premise,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,6,3,Premise,Premise,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","Most risks and benefits dissipated postintervention,"
24084921,6,4,Premise,Premise,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,6,5,Premise,Premise,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,6,7,Premise,Premise,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,6,8,Premise,Claim,support,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,6,9,Premise,Claim,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,6,10,Premise,Claim,none,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age).",although it is appropriate for symptom management in some women.
24084921,7,1,Premise,Premise,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,7,2,Premise,Premise,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,7,3,Premise,Premise,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","Most risks and benefits dissipated postintervention,"
24084921,7,4,Premise,Premise,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,7,5,Premise,Premise,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,7,6,Premise,Premise,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,7,8,Premise,Claim,support,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,7,9,Premise,Claim,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.","Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,7,10,Premise,Claim,none,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.",although it is appropriate for symptom management in some women.
24084921,8,1,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,8,2,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,8,3,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"Most risks and benefits dissipated postintervention,"
24084921,8,4,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,8,5,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,8,6,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,8,7,Claim,Premise,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,8,9,Claim,Claim,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,8,10,Claim,Claim,none,Menopausal hormone therapy has a complex pattern of risks and benefits.,although it is appropriate for symptom management in some women.
24084921,9,1,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,9,2,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,9,3,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","Most risks and benefits dissipated postintervention,"
24084921,9,4,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,9,5,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,9,6,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,9,7,Claim,Premise,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,","Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,9,8,Claim,Claim,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,",Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,9,10,Claim,Claim,none,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,",although it is appropriate for symptom management in some women.
24084921,10,1,Claim,Premise,none,although it is appropriate for symptom management in some women.,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,10,2,Claim,Premise,none,although it is appropriate for symptom management in some women.,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,10,3,Claim,Premise,none,although it is appropriate for symptom management in some women.,"Most risks and benefits dissipated postintervention,"
24084921,10,4,Claim,Premise,none,although it is appropriate for symptom management in some women.,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,10,5,Claim,Premise,none,although it is appropriate for symptom management in some women.,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,10,6,Claim,Premise,none,although it is appropriate for symptom management in some women.,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age)."
24084921,10,7,Claim,Premise,none,although it is appropriate for symptom management in some women.,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,10,8,Claim,Claim,none,although it is appropriate for symptom management in some women.,Menopausal hormone therapy has a complex pattern of risks and benefits.
24084921,10,9,Claim,Claim,support,although it is appropriate for symptom management in some women.,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
22011650,1,2,Premise,Premise,none,"Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001).","Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4)."
22011650,1,3,Premise,Premise,none,"Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001).",Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved.
22011650,1,4,Premise,Claim,support,"Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001).",HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors.
22011650,2,1,Premise,Premise,none,"Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4).","Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001)."
22011650,2,3,Premise,Premise,none,"Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4).",Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved.
22011650,2,4,Premise,Claim,support,"Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4).",HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors.
22011650,3,1,Premise,Premise,none,Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved.,"Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001)."
22011650,3,2,Premise,Premise,none,Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved.,"Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4)."
22011650,3,4,Premise,Claim,support,Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved.,HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors.
22011650,4,1,Claim,Premise,none,HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors.,"Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001)."
22011650,4,2,Claim,Premise,none,HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors.,"Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4)."
22011650,4,3,Claim,Premise,none,HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors.,Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved.
20339140,1,2,Premise,Premise,none,"After a median follow-up time of 9.64 months, incidence rates of grades 2-4 acute diarrhea were similar in both groups (49% placebo vs 44% LAO; P = .21).","No statistically significant treatment differences in chemotherapy or radiation delivery, medical resource utilization, patient-reported bowel function, or QoL were observed."
20339140,1,3,Premise,Claim,support,"After a median follow-up time of 9.64 months, incidence rates of grades 2-4 acute diarrhea were similar in both groups (49% placebo vs 44% LAO; P = .21).","In this study, the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL."
20339140,2,1,Premise,Premise,none,"No statistically significant treatment differences in chemotherapy or radiation delivery, medical resource utilization, patient-reported bowel function, or QoL were observed.","After a median follow-up time of 9.64 months, incidence rates of grades 2-4 acute diarrhea were similar in both groups (49% placebo vs 44% LAO; P = .21)."
20339140,2,3,Premise,Claim,support,"No statistically significant treatment differences in chemotherapy or radiation delivery, medical resource utilization, patient-reported bowel function, or QoL were observed.","In this study, the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL."
20339140,3,1,Claim,Premise,none,"In this study, the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL.","After a median follow-up time of 9.64 months, incidence rates of grades 2-4 acute diarrhea were similar in both groups (49% placebo vs 44% LAO; P = .21)."
20339140,3,2,Claim,Premise,none,"In this study, the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL.","No statistically significant treatment differences in chemotherapy or radiation delivery, medical resource utilization, patient-reported bowel function, or QoL were observed."
11766999,1,2,Claim,Claim,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.","Prompt diagnosis and effective treatment is, therefore, essential."
11766999,1,3,Claim,Premise,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.","After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,1,4,Claim,Premise,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.",Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,1,5,Claim,Claim,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.",A steady improvement in quality of life was also observed in both groups.
11766999,1,6,Claim,Premise,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.",There were no clinically significant differences between the groups.
11766999,1,7,Claim,Premise,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.","In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,1,8,Claim,Premise,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.",Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,1,9,Claim,Claim,none,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.",paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,2,1,Claim,Claim,none,"Prompt diagnosis and effective treatment is, therefore, essential.","In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,2,3,Claim,Premise,none,"Prompt diagnosis and effective treatment is, therefore, essential.","After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,2,4,Claim,Premise,none,"Prompt diagnosis and effective treatment is, therefore, essential.",Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,2,5,Claim,Claim,none,"Prompt diagnosis and effective treatment is, therefore, essential.",A steady improvement in quality of life was also observed in both groups.
11766999,2,6,Claim,Premise,none,"Prompt diagnosis and effective treatment is, therefore, essential.",There were no clinically significant differences between the groups.
11766999,2,7,Claim,Premise,none,"Prompt diagnosis and effective treatment is, therefore, essential.","In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,2,8,Claim,Premise,none,"Prompt diagnosis and effective treatment is, therefore, essential.",Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,2,9,Claim,Claim,none,"Prompt diagnosis and effective treatment is, therefore, essential.",paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,3,1,Premise,Claim,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.","In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,3,2,Premise,Claim,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.","Prompt diagnosis and effective treatment is, therefore, essential."
11766999,3,4,Premise,Premise,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.",Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,3,5,Premise,Claim,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.",A steady improvement in quality of life was also observed in both groups.
11766999,3,6,Premise,Premise,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.",There were no clinically significant differences between the groups.
11766999,3,7,Premise,Premise,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.","In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,3,8,Premise,Premise,none,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.",Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,3,9,Premise,Claim,support,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.",paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,4,1,Premise,Claim,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,4,2,Premise,Claim,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,"Prompt diagnosis and effective treatment is, therefore, essential."
11766999,4,3,Premise,Premise,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,4,5,Premise,Claim,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,A steady improvement in quality of life was also observed in both groups.
11766999,4,6,Premise,Premise,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,There were no clinically significant differences between the groups.
11766999,4,7,Premise,Premise,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,4,8,Premise,Premise,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,4,9,Premise,Claim,none,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,5,1,Claim,Claim,none,A steady improvement in quality of life was also observed in both groups.,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,5,2,Claim,Claim,none,A steady improvement in quality of life was also observed in both groups.,"Prompt diagnosis and effective treatment is, therefore, essential."
11766999,5,3,Claim,Premise,none,A steady improvement in quality of life was also observed in both groups.,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,5,4,Claim,Premise,none,A steady improvement in quality of life was also observed in both groups.,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,5,6,Claim,Premise,none,A steady improvement in quality of life was also observed in both groups.,There were no clinically significant differences between the groups.
11766999,5,7,Claim,Premise,none,A steady improvement in quality of life was also observed in both groups.,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,5,8,Claim,Premise,none,A steady improvement in quality of life was also observed in both groups.,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,5,9,Claim,Claim,support,A steady improvement in quality of life was also observed in both groups.,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,6,1,Premise,Claim,none,There were no clinically significant differences between the groups.,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,6,2,Premise,Claim,none,There were no clinically significant differences between the groups.,"Prompt diagnosis and effective treatment is, therefore, essential."
11766999,6,3,Premise,Premise,none,There were no clinically significant differences between the groups.,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,6,4,Premise,Premise,none,There were no clinically significant differences between the groups.,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,6,5,Premise,Claim,none,There were no clinically significant differences between the groups.,A steady improvement in quality of life was also observed in both groups.
11766999,6,7,Premise,Premise,none,There were no clinically significant differences between the groups.,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,6,8,Premise,Premise,none,There were no clinically significant differences between the groups.,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,6,9,Premise,Claim,support,There were no clinically significant differences between the groups.,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,7,1,Premise,Claim,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.","In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,7,2,Premise,Claim,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.","Prompt diagnosis and effective treatment is, therefore, essential."
11766999,7,3,Premise,Premise,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.","After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,7,4,Premise,Premise,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.",Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,7,5,Premise,Claim,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.",A steady improvement in quality of life was also observed in both groups.
11766999,7,6,Premise,Premise,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.",There were no clinically significant differences between the groups.
11766999,7,8,Premise,Premise,none,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.",Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
11766999,7,9,Premise,Claim,support,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.",paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,8,1,Premise,Claim,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,8,2,Premise,Claim,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,"Prompt diagnosis and effective treatment is, therefore, essential."
11766999,8,3,Premise,Premise,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,8,4,Premise,Premise,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,8,5,Premise,Claim,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,A steady improvement in quality of life was also observed in both groups.
11766999,8,6,Premise,Premise,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,There were no clinically significant differences between the groups.
11766999,8,7,Premise,Premise,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,8,9,Premise,Claim,none,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
11766999,9,1,Claim,Claim,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,9,2,Claim,Claim,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,"Prompt diagnosis and effective treatment is, therefore, essential."
11766999,9,3,Claim,Premise,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,9,4,Claim,Premise,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
11766999,9,5,Claim,Claim,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,A steady improvement in quality of life was also observed in both groups.
11766999,9,6,Claim,Premise,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,There were no clinically significant differences between the groups.
11766999,9,7,Claim,Premise,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,9,8,Claim,Premise,none,paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.,Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
19704057,1,2,Premise,Premise,none,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072).","After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
19704057,1,3,Premise,Premise,none,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072).",The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.
19704057,1,4,Premise,Premise,none,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072).","Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,1,5,Premise,Premise,none,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072).","The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,1,6,Premise,Claim,support,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072).",Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
19704057,1,7,Premise,Premise,none,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072).","Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,2,1,Premise,Premise,none,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group.","Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,2,3,Premise,Premise,none,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group.",The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.
19704057,2,4,Premise,Premise,none,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group.","Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,2,5,Premise,Premise,none,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group.","The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,2,6,Premise,Claim,support,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group.",Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
19704057,2,7,Premise,Premise,none,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group.","Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,3,1,Premise,Premise,none,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,3,2,Premise,Premise,none,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
19704057,3,4,Premise,Premise,none,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,3,5,Premise,Premise,none,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,3,6,Premise,Claim,support,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
19704057,3,7,Premise,Premise,none,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.,"Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,4,1,Premise,Premise,none,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively.","Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,4,2,Premise,Premise,none,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively.","After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
19704057,4,3,Premise,Premise,none,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively.",The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.
19704057,4,5,Premise,Premise,none,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively.","The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,4,6,Premise,Claim,support,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively.",Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
19704057,4,7,Premise,Premise,none,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively.","Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,5,1,Premise,Premise,none,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).","Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,5,2,Premise,Premise,none,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).","After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
19704057,5,3,Premise,Premise,none,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).",The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.
19704057,5,4,Premise,Premise,none,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).","Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,5,6,Premise,Claim,none,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).",Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
19704057,5,7,Premise,Premise,none,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).","Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,6,1,Claim,Premise,none,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,6,2,Claim,Premise,none,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
19704057,6,3,Claim,Premise,none,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.,The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.
19704057,6,4,Claim,Premise,none,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,6,5,Claim,Premise,none,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,6,7,Claim,Premise,none,Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.,"Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,7,1,Premise,Premise,none,"Because of the low number of observed deaths, survival analysis was not confirmatory.","Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,7,2,Premise,Premise,none,"Because of the low number of observed deaths, survival analysis was not confirmatory.","After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
19704057,7,3,Premise,Premise,none,"Because of the low number of observed deaths, survival analysis was not confirmatory.",The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.
19704057,7,4,Premise,Premise,none,"Because of the low number of observed deaths, survival analysis was not confirmatory.","Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,7,5,Premise,Premise,attack,"Because of the low number of observed deaths, survival analysis was not confirmatory.","The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,7,6,Premise,Claim,none,"Because of the low number of observed deaths, survival analysis was not confirmatory.",Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
21296449,1,2,Premise,Premise,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.",There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,1,3,Premise,Premise,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.","No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,1,4,Premise,Premise,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.","There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,1,5,Premise,Premise,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.",There was no difference in OS (p=0.992).
21296449,1,6,Premise,Premise,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.","Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,1,7,Premise,Claim,support,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.",Clinical efficacy of docetaxel was observed at all dose levels.
21296449,1,8,Premise,Claim,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.","Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,1,9,Premise,Premise,none,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%.",the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,2,1,Premise,Premise,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,2,3,Premise,Premise,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,2,4,Premise,Premise,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,2,5,Premise,Premise,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,There was no difference in OS (p=0.992).
21296449,2,6,Premise,Premise,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,2,7,Premise,Claim,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,Clinical efficacy of docetaxel was observed at all dose levels.
21296449,2,8,Premise,Claim,support,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,2,9,Premise,Premise,none,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,3,1,Premise,Premise,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.","There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,3,2,Premise,Premise,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.",There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,3,4,Premise,Premise,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.","There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,3,5,Premise,Premise,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.",There was no difference in OS (p=0.992).
21296449,3,6,Premise,Premise,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.","Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,3,7,Premise,Claim,support,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.",Clinical efficacy of docetaxel was observed at all dose levels.
21296449,3,8,Premise,Claim,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.","Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,3,9,Premise,Premise,none,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity.",the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,4,1,Premise,Premise,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).","There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,4,2,Premise,Premise,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).",There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,4,3,Premise,Premise,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).","No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,4,5,Premise,Premise,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).",There was no difference in OS (p=0.992).
21296449,4,6,Premise,Premise,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).","Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,4,7,Premise,Claim,support,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).",Clinical efficacy of docetaxel was observed at all dose levels.
21296449,4,8,Premise,Claim,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).","Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,4,9,Premise,Premise,none,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively).",the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,5,1,Premise,Premise,none,There was no difference in OS (p=0.992).,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,5,2,Premise,Premise,none,There was no difference in OS (p=0.992).,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,5,3,Premise,Premise,none,There was no difference in OS (p=0.992).,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,5,4,Premise,Premise,none,There was no difference in OS (p=0.992).,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,5,6,Premise,Premise,none,There was no difference in OS (p=0.992).,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,5,7,Premise,Claim,support,There was no difference in OS (p=0.992).,Clinical efficacy of docetaxel was observed at all dose levels.
21296449,5,8,Premise,Claim,none,There was no difference in OS (p=0.992).,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,5,9,Premise,Premise,none,There was no difference in OS (p=0.992).,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,6,1,Premise,Premise,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.","There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,6,2,Premise,Premise,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.",There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,6,3,Premise,Premise,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.","No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,6,4,Premise,Premise,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.","There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,6,5,Premise,Premise,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.",There was no difference in OS (p=0.992).
21296449,6,7,Premise,Claim,support,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.",Clinical efficacy of docetaxel was observed at all dose levels.
21296449,6,8,Premise,Claim,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.","Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,6,9,Premise,Premise,none,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively.",the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,7,1,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,7,2,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,7,3,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,7,4,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,7,5,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,There was no difference in OS (p=0.992).
21296449,7,6,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,7,8,Claim,Claim,none,Clinical efficacy of docetaxel was observed at all dose levels.,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,7,9,Claim,Premise,none,Clinical efficacy of docetaxel was observed at all dose levels.,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,8,1,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.","There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,8,2,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.",There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,8,3,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.","No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,8,4,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.","There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,8,5,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.",There was no difference in OS (p=0.992).
21296449,8,6,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.","Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,8,7,Claim,Claim,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.",Clinical efficacy of docetaxel was observed at all dose levels.
21296449,8,9,Claim,Premise,none,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates.",the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.
21296449,9,1,Premise,Premise,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,9,2,Premise,Premise,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms.
21296449,9,3,Premise,Premise,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,9,4,Premise,Premise,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,9,5,Premise,Premise,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,There was no difference in OS (p=0.992).
21296449,9,6,Premise,Premise,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,9,7,Premise,Claim,attack,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,Clinical efficacy of docetaxel was observed at all dose levels.
21296449,9,8,Premise,Claim,none,the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population.,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
20227168,1,2,Premise,Premise,none,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018).","At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028)."
20227168,1,3,Premise,Premise,none,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018).",The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).
20227168,1,4,Premise,Premise,none,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018).","In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001)."
20227168,1,5,Premise,Claim,support,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018).",Preoperative PFME may improve early continence and QoL outcomes after RP.
20227168,1,6,Premise,Claim,none,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018).",Further studies are needed to corroborate our results.
20227168,2,1,Premise,Premise,none,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028).","After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018)."
20227168,2,3,Premise,Premise,none,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028).",The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).
20227168,2,4,Premise,Premise,none,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028).","In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001)."
20227168,2,5,Premise,Claim,support,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028).",Preoperative PFME may improve early continence and QoL outcomes after RP.
20227168,2,6,Premise,Claim,none,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028).",Further studies are needed to corroborate our results.
20227168,3,1,Premise,Premise,none,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018)."
20227168,3,2,Premise,Premise,none,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028)."
20227168,3,4,Premise,Premise,none,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001)."
20227168,3,5,Premise,Claim,support,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).,Preoperative PFME may improve early continence and QoL outcomes after RP.
20227168,3,6,Premise,Claim,none,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).,Further studies are needed to corroborate our results.
20227168,4,1,Premise,Premise,none,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001).","After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018)."
20227168,4,2,Premise,Premise,none,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001).","At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028)."
20227168,4,3,Premise,Premise,none,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001).",The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).
20227168,4,5,Premise,Claim,support,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001).",Preoperative PFME may improve early continence and QoL outcomes after RP.
20227168,4,6,Premise,Claim,none,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001).",Further studies are needed to corroborate our results.
20227168,5,1,Claim,Premise,none,Preoperative PFME may improve early continence and QoL outcomes after RP.,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018)."
20227168,5,2,Claim,Premise,none,Preoperative PFME may improve early continence and QoL outcomes after RP.,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028)."
20227168,5,3,Claim,Premise,none,Preoperative PFME may improve early continence and QoL outcomes after RP.,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).
20227168,5,4,Claim,Premise,none,Preoperative PFME may improve early continence and QoL outcomes after RP.,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001)."
20227168,5,6,Claim,Claim,none,Preoperative PFME may improve early continence and QoL outcomes after RP.,Further studies are needed to corroborate our results.
20227168,6,1,Claim,Premise,none,Further studies are needed to corroborate our results.,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018)."
20227168,6,2,Claim,Premise,none,Further studies are needed to corroborate our results.,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028)."
20227168,6,3,Claim,Premise,none,Further studies are needed to corroborate our results.,The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002).
20227168,6,4,Claim,Premise,none,Further studies are needed to corroborate our results.,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p0.001)."
20227168,6,5,Claim,Claim,attack,Further studies are needed to corroborate our results.,Preoperative PFME may improve early continence and QoL outcomes after RP.
20009826,1,2,Premise,Premise,none,Results were correlated with previously reported objective sensibility outcomes.,There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.
20009826,1,3,Premise,Claim,support,Results were correlated with previously reported objective sensibility outcomes.,This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.
20009826,2,1,Premise,Premise,none,There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.,Results were correlated with previously reported objective sensibility outcomes.
20009826,2,3,Premise,Claim,support,There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.,This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.
20009826,3,1,Claim,Premise,none,This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.,Results were correlated with previously reported objective sensibility outcomes.
20009826,3,2,Claim,Premise,none,This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.,There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.
24123482,1,2,Premise,Premise,none,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,1,3,Premise,Premise,none,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,1,4,Premise,Premise,none,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,1,5,Premise,Premise,none,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,1,6,Premise,Claim,support,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,1,7,Premise,Claim,none,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,1,8,Premise,Claim,none,"The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78).","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,2,1,Premise,Premise,none,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,2,3,Premise,Premise,none,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,2,4,Premise,Premise,none,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,2,5,Premise,Premise,none,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,2,6,Premise,Claim,none,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,2,7,Premise,Claim,support,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,2,8,Premise,Claim,none,"the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05).","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,3,1,Premise,Premise,none,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,3,2,Premise,Premise,none,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,3,4,Premise,Premise,none,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,3,5,Premise,Premise,none,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,3,6,Premise,Claim,support,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,3,7,Premise,Claim,none,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,3,8,Premise,Claim,none,"The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38).","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,4,1,Premise,Premise,none,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,4,2,Premise,Premise,none,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,4,3,Premise,Premise,none,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,4,5,Premise,Premise,none,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,4,6,Premise,Claim,support,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,4,7,Premise,Claim,none,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,4,8,Premise,Claim,none,"Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL.","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,5,1,Premise,Premise,none,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,5,2,Premise,Premise,none,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,5,3,Premise,Premise,none,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,5,4,Premise,Premise,none,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,5,6,Premise,Claim,support,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,5,7,Premise,Claim,none,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,5,8,Premise,Claim,none,"increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54).","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,6,1,Claim,Premise,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,6,2,Claim,Premise,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,6,3,Claim,Premise,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,6,4,Claim,Premise,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,6,5,Claim,Premise,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,6,7,Claim,Claim,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,6,8,Claim,Claim,none,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress.","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,7,1,Claim,Premise,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,7,2,Claim,Premise,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,7,3,Claim,Premise,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,7,4,Claim,Premise,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,7,5,Claim,Premise,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,7,6,Claim,Claim,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,7,8,Claim,Claim,none,"In addition to physical activity, future interventions should target self-efficacy and mastery.","This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,8,1,Claim,Premise,none,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","The intervention was associated with increased physical activity ( = 0.46, 95% confidence interval (CI)= 0.14;0.59), general self-efficacy ( = 2.41, 95%CI = 0.35;4.73), and mastery ( = 1.75, 95%CI = 0.36;2.78)."
24123482,8,2,Claim,Premise,none,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","the intervention had both a direct effect on fatigue ( =-1.09, 95%CI =-2.12;0.01), and an indirect effect ( =-0.54, 95%CI =-1.00;-0.21) via physical activity ( =-0.29, 95%CI = -0.64;-0.07) and general self-efficacy ( =-0.25, 95%CI =-0.61;-0.05)."
24123482,8,3,Claim,Premise,none,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","The intervention had a borderline significant direct effect on reduced distress ( = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery ( = -1.06, 95%CI = -1.89;-0.38)."
24123482,8,4,Claim,Premise,none,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","Reductions in fatigue ( = -1.33, 95%CI=-1.85;-0.83) and distress ( = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,8,5,Claim,Premise,none,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","increased physical activity was directly associated with improved QoL ( = 3.37, 95%CI = 1.01;5.54)."
24123482,8,6,Claim,Claim,none,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,8,7,Claim,Claim,support,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors.","In addition to physical activity, future interventions should target self-efficacy and mastery."
21366974,1,2,Premise,Premise,none,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects.","These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia."
21366974,1,3,Premise,Premise,none,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects.","No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81)."
21366974,1,4,Premise,Claim,none,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects.",Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).
21366974,1,5,Premise,Claim,attack,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects.",our results show that the addition of RT does not impair overall quality of life.
21366974,1,6,Premise,Claim,none,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects.",Further economic modelling on the longer-term costs and consequences of omitting RT is required.
21366974,2,1,Premise,Premise,support,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia.","RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects."
21366974,2,3,Premise,Premise,none,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia.","No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81)."
21366974,2,4,Premise,Claim,none,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia.",Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).
21366974,2,5,Premise,Claim,none,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia.",our results show that the addition of RT does not impair overall quality of life.
21366974,2,6,Premise,Claim,none,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia.",Further economic modelling on the longer-term costs and consequences of omitting RT is required.
21366974,3,1,Premise,Premise,none,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81).","RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects."
21366974,3,2,Premise,Premise,none,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81).","These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia."
21366974,3,4,Premise,Claim,support,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81).",Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).
21366974,3,5,Premise,Claim,none,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81).",our results show that the addition of RT does not impair overall quality of life.
21366974,3,6,Premise,Claim,none,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81).",Further economic modelling on the longer-term costs and consequences of omitting RT is required.
21366974,4,1,Claim,Premise,none,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects."
21366974,4,2,Claim,Premise,none,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia."
21366974,4,3,Claim,Premise,none,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81)."
21366974,4,5,Claim,Claim,support,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).,our results show that the addition of RT does not impair overall quality of life.
21366974,4,6,Claim,Claim,none,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).,Further economic modelling on the longer-term costs and consequences of omitting RT is required.
21366974,5,1,Claim,Premise,none,our results show that the addition of RT does not impair overall quality of life.,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects."
21366974,5,2,Claim,Premise,none,our results show that the addition of RT does not impair overall quality of life.,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia."
21366974,5,3,Claim,Premise,none,our results show that the addition of RT does not impair overall quality of life.,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81)."
21366974,5,4,Claim,Claim,none,our results show that the addition of RT does not impair overall quality of life.,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).
21366974,5,6,Claim,Claim,none,our results show that the addition of RT does not impair overall quality of life.,Further economic modelling on the longer-term costs and consequences of omitting RT is required.
21366974,6,1,Claim,Premise,none,Further economic modelling on the longer-term costs and consequences of omitting RT is required.,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects."
21366974,6,2,Claim,Premise,none,Further economic modelling on the longer-term costs and consequences of omitting RT is required.,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia."
21366974,6,3,Claim,Premise,none,Further economic modelling on the longer-term costs and consequences of omitting RT is required.,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81)."
21366974,6,4,Claim,Claim,none,Further economic modelling on the longer-term costs and consequences of omitting RT is required.,Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL).
21366974,6,5,Claim,Claim,attack,Further economic modelling on the longer-term costs and consequences of omitting RT is required.,our results show that the addition of RT does not impair overall quality of life.
23333117,1,2,Premise,Premise,none,"Overall, the mean global QoL score improved during chemotherapy by 72 points (SD 244) when analysed for all women with data at baseline and week 18.","The mean global QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab group (761 [SD 182] vs 697 [191] points; difference 64 points, 95% CI 37-90, p<00001)."
23333117,1,3,Premise,Claim,attack,"Overall, the mean global QoL score improved during chemotherapy by 72 points (SD 244) when analysed for all women with data at baseline and week 18.",Bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer.
23333117,2,1,Premise,Premise,none,"The mean global QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab group (761 [SD 182] vs 697 [191] points; difference 64 points, 95% CI 37-90, p<00001).","Overall, the mean global QoL score improved during chemotherapy by 72 points (SD 244) when analysed for all women with data at baseline and week 18."
23333117,2,3,Premise,Claim,support,"The mean global QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab group (761 [SD 182] vs 697 [191] points; difference 64 points, 95% CI 37-90, p<00001).",Bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer.
23333117,3,1,Claim,Premise,none,Bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer.,"Overall, the mean global QoL score improved during chemotherapy by 72 points (SD 244) when analysed for all women with data at baseline and week 18."
23333117,3,2,Claim,Premise,none,Bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer.,"The mean global QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab group (761 [SD 182] vs 697 [191] points; difference 64 points, 95% CI 37-90, p<00001)."
20362386,1,2,Premise,Premise,none,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686).",Urinary retention occurred only in one case (control group).
20362386,1,3,Premise,Premise,none,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686).",The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.
20362386,1,4,Premise,Premise,none,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686).","Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations."
20362386,1,5,Premise,Premise,none,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686).",No significant difference in any of the analysed outcome measures was observed.
20362386,1,6,Premise,Claim,support,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686).",Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.
20362386,2,1,Premise,Premise,none,Urinary retention occurred only in one case (control group).,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686)."
20362386,2,3,Premise,Premise,none,Urinary retention occurred only in one case (control group).,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.
20362386,2,4,Premise,Premise,none,Urinary retention occurred only in one case (control group).,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations."
20362386,2,5,Premise,Premise,none,Urinary retention occurred only in one case (control group).,No significant difference in any of the analysed outcome measures was observed.
20362386,2,6,Premise,Claim,support,Urinary retention occurred only in one case (control group).,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.
20362386,3,1,Premise,Premise,none,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686)."
20362386,3,2,Premise,Premise,none,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.,Urinary retention occurred only in one case (control group).
20362386,3,4,Premise,Premise,none,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations."
20362386,3,5,Premise,Premise,none,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.,No significant difference in any of the analysed outcome measures was observed.
20362386,3,6,Premise,Claim,support,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.
20362386,4,1,Premise,Premise,none,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations.","For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686)."
20362386,4,2,Premise,Premise,none,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations.",Urinary retention occurred only in one case (control group).
20362386,4,3,Premise,Premise,none,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations.",The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.
20362386,4,5,Premise,Premise,none,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations.",No significant difference in any of the analysed outcome measures was observed.
20362386,4,6,Premise,Claim,attack,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations.",Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.
20362386,5,1,Premise,Premise,none,No significant difference in any of the analysed outcome measures was observed.,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686)."
20362386,5,2,Premise,Premise,none,No significant difference in any of the analysed outcome measures was observed.,Urinary retention occurred only in one case (control group).
20362386,5,3,Premise,Premise,none,No significant difference in any of the analysed outcome measures was observed.,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.
20362386,5,4,Premise,Premise,none,No significant difference in any of the analysed outcome measures was observed.,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations."
20362386,5,6,Premise,Claim,support,No significant difference in any of the analysed outcome measures was observed.,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.
20362386,6,1,Claim,Premise,none,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686)."
20362386,6,2,Claim,Premise,none,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.,Urinary retention occurred only in one case (control group).
20362386,6,3,Claim,Premise,none,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.,The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups.
20362386,6,4,Claim,Premise,none,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations."
20362386,6,5,Claim,Premise,none,Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP.,No significant difference in any of the analysed outcome measures was observed.
16487438,1,2,MajorClaim,Premise,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,1,3,MajorClaim,Premise,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,1,4,MajorClaim,Premise,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,although this parameter did not differ from the reference group at baseline.
16487438,1,5,MajorClaim,Premise,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,1,6,MajorClaim,Premise,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,No improvement in the SDQ score was observed.
16487438,1,7,MajorClaim,Claim,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,1,8,MajorClaim,Claim,none,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.,Restoration of euthyroidism in general does not affect quality of life.
16487438,2,1,Premise,MajorClaim,none,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.",The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,2,3,Premise,Premise,none,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.","In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,2,4,Premise,Premise,none,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.",although this parameter did not differ from the reference group at baseline.
16487438,2,5,Premise,Premise,none,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.",A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,2,6,Premise,Premise,none,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.",No improvement in the SDQ score was observed.
16487438,2,7,Premise,Claim,none,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.","In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,2,8,Premise,Claim,support,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values.",Restoration of euthyroidism in general does not affect quality of life.
16487438,3,1,Premise,MajorClaim,none,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),",The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,3,2,Premise,Premise,none,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),","After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,3,4,Premise,Premise,none,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),",although this parameter did not differ from the reference group at baseline.
16487438,3,5,Premise,Premise,none,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),",A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,3,6,Premise,Premise,none,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),",No improvement in the SDQ score was observed.
16487438,3,7,Premise,Claim,support,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),","In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,3,8,Premise,Claim,none,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),",Restoration of euthyroidism in general does not affect quality of life.
16487438,4,1,Premise,MajorClaim,none,although this parameter did not differ from the reference group at baseline.,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,4,2,Premise,Premise,none,although this parameter did not differ from the reference group at baseline.,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,4,3,Premise,Premise,attack,although this parameter did not differ from the reference group at baseline.,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,4,5,Premise,Premise,none,although this parameter did not differ from the reference group at baseline.,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,4,6,Premise,Premise,none,although this parameter did not differ from the reference group at baseline.,No improvement in the SDQ score was observed.
16487438,4,7,Premise,Claim,none,although this parameter did not differ from the reference group at baseline.,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,4,8,Premise,Claim,none,although this parameter did not differ from the reference group at baseline.,Restoration of euthyroidism in general does not affect quality of life.
16487438,5,1,Premise,MajorClaim,none,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,5,2,Premise,Premise,none,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,5,3,Premise,Premise,none,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,5,4,Premise,Premise,none,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,although this parameter did not differ from the reference group at baseline.
16487438,5,6,Premise,Premise,none,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,No improvement in the SDQ score was observed.
16487438,5,7,Premise,Claim,attack,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,5,8,Premise,Claim,none,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.,Restoration of euthyroidism in general does not affect quality of life.
16487438,6,1,Premise,MajorClaim,none,No improvement in the SDQ score was observed.,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,6,2,Premise,Premise,none,No improvement in the SDQ score was observed.,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,6,3,Premise,Premise,none,No improvement in the SDQ score was observed.,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,6,4,Premise,Premise,none,No improvement in the SDQ score was observed.,although this parameter did not differ from the reference group at baseline.
16487438,6,5,Premise,Premise,none,No improvement in the SDQ score was observed.,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,6,7,Premise,Claim,none,No improvement in the SDQ score was observed.,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,6,8,Premise,Claim,support,No improvement in the SDQ score was observed.,Restoration of euthyroidism in general does not affect quality of life.
16487438,7,1,Claim,MajorClaim,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.",The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,7,2,Claim,Premise,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.","After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,7,3,Claim,Premise,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.","In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,7,4,Claim,Premise,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.",although this parameter did not differ from the reference group at baseline.
16487438,7,5,Claim,Premise,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.",A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,7,6,Claim,Premise,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.",No improvement in the SDQ score was observed.
16487438,7,8,Claim,Claim,none,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved.",Restoration of euthyroidism in general does not affect quality of life.
16487438,8,1,Claim,MajorClaim,none,Restoration of euthyroidism in general does not affect quality of life.,The impact of prolonged subclinical hyperthyroidism on quality of life is unclear.
16487438,8,2,Claim,Premise,none,Restoration of euthyroidism in general does not affect quality of life.,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,8,3,Claim,Premise,none,Restoration of euthyroidism in general does not affect quality of life.,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,8,4,Claim,Premise,none,Restoration of euthyroidism in general does not affect quality of life.,although this parameter did not differ from the reference group at baseline.
16487438,8,5,Claim,Premise,none,Restoration of euthyroidism in general does not affect quality of life.,A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed.
16487438,8,6,Claim,Premise,none,Restoration of euthyroidism in general does not affect quality of life.,No improvement in the SDQ score was observed.
16487438,8,7,Claim,Claim,none,Restoration of euthyroidism in general does not affect quality of life.,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
11790211,1,2,Claim,MajorClaim,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,"The safety and efficacy of LAC for colon cancer are unknown,"
11790211,1,3,Claim,MajorClaim,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,1,4,Claim,Premise,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,1,5,Claim,Premise,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,1,6,Claim,Premise,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,1,7,Claim,Claim,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
11790211,1,8,Claim,Claim,none,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,2,1,MajorClaim,Claim,none,"The safety and efficacy of LAC for colon cancer are unknown,",Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,2,3,MajorClaim,MajorClaim,none,"The safety and efficacy of LAC for colon cancer are unknown,",the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,2,4,MajorClaim,Premise,none,"The safety and efficacy of LAC for colon cancer are unknown,","In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,2,5,MajorClaim,Premise,none,"The safety and efficacy of LAC for colon cancer are unknown,",The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,2,6,MajorClaim,Premise,none,"The safety and efficacy of LAC for colon cancer are unknown,","While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,2,7,MajorClaim,Claim,none,"The safety and efficacy of LAC for colon cancer are unknown,",Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
11790211,2,8,MajorClaim,Claim,none,"The safety and efficacy of LAC for colon cancer are unknown,","Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,3,1,MajorClaim,Claim,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,3,2,MajorClaim,MajorClaim,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,"The safety and efficacy of LAC for colon cancer are unknown,"
11790211,3,4,MajorClaim,Premise,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,3,5,MajorClaim,Premise,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,3,6,MajorClaim,Premise,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,3,7,MajorClaim,Claim,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
11790211,3,8,MajorClaim,Claim,none,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,4,1,Premise,Claim,none,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.",Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,4,2,Premise,MajorClaim,none,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.","The safety and efficacy of LAC for colon cancer are unknown,"
11790211,4,3,Premise,MajorClaim,none,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.",the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,4,5,Premise,Premise,none,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.",The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,4,6,Premise,Premise,none,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.","While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,4,7,Premise,Claim,support,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.",Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
11790211,4,8,Premise,Claim,none,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery.","Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,5,1,Premise,Claim,none,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,5,2,Premise,MajorClaim,none,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,"The safety and efficacy of LAC for colon cancer are unknown,"
11790211,5,3,Premise,MajorClaim,none,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,5,4,Premise,Premise,none,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,5,6,Premise,Premise,none,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,5,7,Premise,Claim,support,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
11790211,5,8,Premise,Claim,none,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,6,1,Premise,Claim,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).",Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,6,2,Premise,MajorClaim,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).","The safety and efficacy of LAC for colon cancer are unknown,"
11790211,6,3,Premise,MajorClaim,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).",the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,6,4,Premise,Premise,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).","In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,6,5,Premise,Premise,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).",The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,6,7,Premise,Claim,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).",Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
11790211,6,8,Premise,Claim,none,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).","Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,7,1,Claim,Claim,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,7,2,Claim,MajorClaim,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,"The safety and efficacy of LAC for colon cancer are unknown,"
11790211,7,3,Claim,MajorClaim,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,7,4,Claim,Premise,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,7,5,Claim,Premise,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,7,6,Claim,Premise,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,7,8,Claim,Claim,none,Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11790211,8,1,Claim,Claim,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.",Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon.
11790211,8,2,Claim,MajorClaim,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.","The safety and efficacy of LAC for colon cancer are unknown,"
11790211,8,3,Claim,MajorClaim,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.",the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
11790211,8,4,Claim,Premise,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.","In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,8,5,Claim,Premise,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.",The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009).
11790211,8,6,Claim,Premise,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.","While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,8,7,Claim,Claim,none,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer.",Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
9093725,1,2,MajorClaim,Premise,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.","More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,1,3,MajorClaim,Premise,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.","A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,1,4,MajorClaim,Premise,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.",Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,1,5,MajorClaim,Premise,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.",although the difference was not statistically significant (P = 0.12).
9093725,1,6,MajorClaim,Premise,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.","After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,1,7,MajorClaim,Premise,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.","Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,1,8,MajorClaim,Claim,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.",The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,1,9,MajorClaim,Claim,none,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.","The number of patients who benefit from treatment is, however, still rather limited."
9093725,2,1,Premise,MajorClaim,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).","The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,2,3,Premise,Premise,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).","A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,2,4,Premise,Premise,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).",Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,2,5,Premise,Premise,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).",although the difference was not statistically significant (P = 0.12).
9093725,2,6,Premise,Premise,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).","After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,2,7,Premise,Premise,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).","Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,2,8,Premise,Claim,support,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).",The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,2,9,Premise,Claim,none,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).","The number of patients who benefit from treatment is, however, still rather limited."
9093725,3,1,Premise,MajorClaim,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).","The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,3,2,Premise,Premise,support,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).","More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,3,4,Premise,Premise,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).",Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,3,5,Premise,Premise,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).",although the difference was not statistically significant (P = 0.12).
9093725,3,6,Premise,Premise,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).","After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,3,7,Premise,Premise,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).","Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,3,8,Premise,Claim,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).",The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,3,9,Premise,Claim,none,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).","The number of patients who benefit from treatment is, however, still rather limited."
9093725,4,1,Premise,MajorClaim,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,4,2,Premise,Premise,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,4,3,Premise,Premise,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,4,5,Premise,Premise,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),although the difference was not statistically significant (P = 0.12).
9093725,4,6,Premise,Premise,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,4,7,Premise,Premise,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,4,8,Premise,Claim,support,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,4,9,Premise,Claim,none,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months),"The number of patients who benefit from treatment is, however, still rather limited."
9093725,5,1,Premise,MajorClaim,none,although the difference was not statistically significant (P = 0.12).,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,5,2,Premise,Premise,none,although the difference was not statistically significant (P = 0.12).,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,5,3,Premise,Premise,none,although the difference was not statistically significant (P = 0.12).,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,5,4,Premise,Premise,attack,although the difference was not statistically significant (P = 0.12).,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,5,6,Premise,Premise,none,although the difference was not statistically significant (P = 0.12).,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,5,7,Premise,Premise,none,although the difference was not statistically significant (P = 0.12).,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,5,8,Premise,Claim,none,although the difference was not statistically significant (P = 0.12).,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,5,9,Premise,Claim,none,although the difference was not statistically significant (P = 0.12).,"The number of patients who benefit from treatment is, however, still rather limited."
9093725,6,1,Premise,MajorClaim,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).","The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,6,2,Premise,Premise,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).","More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,6,3,Premise,Premise,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).","A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,6,4,Premise,Premise,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).",Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,6,5,Premise,Premise,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).",although the difference was not statistically significant (P = 0.12).
9093725,6,7,Premise,Premise,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).","Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,6,8,Premise,Claim,support,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).",The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,6,9,Premise,Claim,none,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).","The number of patients who benefit from treatment is, however, still rather limited."
9093725,7,1,Premise,MajorClaim,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).","The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,7,2,Premise,Premise,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).","More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,7,3,Premise,Premise,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).","A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,7,4,Premise,Premise,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).",Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,7,5,Premise,Premise,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).",although the difference was not statistically significant (P = 0.12).
9093725,7,6,Premise,Premise,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).","After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,7,8,Premise,Claim,support,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).",The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
9093725,7,9,Premise,Claim,none,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).","The number of patients who benefit from treatment is, however, still rather limited."
9093725,8,1,Claim,MajorClaim,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,8,2,Claim,Premise,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,8,3,Claim,Premise,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,8,4,Claim,Premise,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,8,5,Claim,Premise,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,although the difference was not statistically significant (P = 0.12).
9093725,8,6,Claim,Premise,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,8,7,Claim,Premise,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,8,9,Claim,Claim,none,The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.,"The number of patients who benefit from treatment is, however, still rather limited."
9093725,9,1,Claim,MajorClaim,none,"The number of patients who benefit from treatment is, however, still rather limited.","The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,9,2,Claim,Premise,none,"The number of patients who benefit from treatment is, however, still rather limited.","More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,9,3,Claim,Premise,none,"The number of patients who benefit from treatment is, however, still rather limited.","A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,9,4,Claim,Premise,none,"The number of patients who benefit from treatment is, however, still rather limited.",Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
9093725,9,5,Claim,Premise,none,"The number of patients who benefit from treatment is, however, still rather limited.",although the difference was not statistically significant (P = 0.12).
9093725,9,6,Claim,Premise,none,"The number of patients who benefit from treatment is, however, still rather limited.","After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,9,7,Claim,Premise,none,"The number of patients who benefit from treatment is, however, still rather limited.","Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,9,8,Claim,Claim,attack,"The number of patients who benefit from treatment is, however, still rather limited.",The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
22877848,1,2,Premise,Premise,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).","For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,1,3,Premise,Premise,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).","For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,1,4,Premise,Premise,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).","Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,1,5,Premise,Premise,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).",the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,1,6,Premise,Premise,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).",Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,1,7,Premise,Premise,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).",Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,1,8,Premise,Claim,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).","Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,1,9,Premise,Claim,support,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).",Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,1,10,Premise,Claim,none,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024).",MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,2,1,Premise,Premise,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).","In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,2,3,Premise,Premise,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).","For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,2,4,Premise,Premise,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).","Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,2,5,Premise,Premise,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).",the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,2,6,Premise,Premise,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).",Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,2,7,Premise,Premise,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).",Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,2,8,Premise,Claim,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).","Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,2,9,Premise,Claim,support,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).",Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,2,10,Premise,Claim,none,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012).",MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,3,1,Premise,Premise,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).","In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,3,2,Premise,Premise,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).","For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,3,4,Premise,Premise,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).","Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,3,5,Premise,Premise,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).",the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,3,6,Premise,Premise,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).",Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,3,7,Premise,Premise,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).",Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,3,8,Premise,Claim,support,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).","Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,3,9,Premise,Claim,support,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).",Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,3,10,Premise,Claim,none,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002).",MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,4,1,Premise,Premise,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).","In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,4,2,Premise,Premise,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).","For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,4,3,Premise,Premise,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).","For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,4,5,Premise,Premise,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).",the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,4,6,Premise,Premise,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).",Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,4,7,Premise,Premise,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).",Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,4,8,Premise,Claim,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).","Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,4,9,Premise,Claim,none,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).",Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,4,10,Premise,Claim,support,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081).",MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,5,1,Premise,Premise,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,5,2,Premise,Premise,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,5,3,Premise,Premise,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,5,4,Premise,Premise,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,5,6,Premise,Premise,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,5,7,Premise,Premise,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,5,8,Premise,Claim,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,5,9,Premise,Claim,support,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,5,10,Premise,Claim,none,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,6,1,Premise,Premise,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,6,2,Premise,Premise,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,6,3,Premise,Premise,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,6,4,Premise,Premise,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,6,5,Premise,Premise,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,6,7,Premise,Premise,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,6,8,Premise,Claim,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,6,9,Premise,Claim,support,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,6,10,Premise,Claim,none,Grade 3-5 infections in all randomisation groups were reported in 18 patients.,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,7,1,Premise,Premise,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,7,2,Premise,Premise,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,7,3,Premise,Premise,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,7,4,Premise,Premise,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,7,5,Premise,Premise,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,7,6,Premise,Premise,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,7,8,Premise,Claim,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,7,9,Premise,Claim,attack,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,7,10,Premise,Claim,none,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,8,1,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.","In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,8,2,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.","For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,8,3,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.","For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,8,4,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.","Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,8,5,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.",the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,8,6,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.",Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,8,7,Claim,Premise,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.",Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,8,9,Claim,Claim,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.",Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
22877848,8,10,Claim,Claim,none,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years.",MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,9,1,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,9,2,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,9,3,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,9,4,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,9,5,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,9,6,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,9,7,Claim,Premise,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,9,8,Claim,Claim,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,9,10,Claim,Claim,none,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
22877848,10,1,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (83 months [95% CI 71-95; n=93] vs 60 months [95% CI 51-68; n=100], hazard ratio [HR] 070; 95% CI 052-093, p=001), but not with hypofractionated radiotherapy (75 months [65-86; n=98], HR 085 [064-112], p=024)."
22877848,10,2,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (84 months [73-94; n=119] vs 74 months [64-84; n=123]; HR 082, 95% CI 063-106; p=012)."
22877848,10,3,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 035 [021-056], p<00001; HR for hypofractionated vs standard radiotherapy 059 [95% CI 037-093], p=002)."
22877848,10,4,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (97 months [95% CI 80-114] vs 68 months [59-77]; HR 056 [95% CI 034-093], p=002), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 097 [95% CI 069-138]; p=081)."
22877848,10,5,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18).
22877848,10,6,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,Grade 3-5 infections in all randomisation groups were reported in 18 patients.
22877848,10,7,Claim,Premise,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed.
22877848,10,8,Claim,Claim,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,10,9,Claim,Claim,none,MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.,Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma.
16483488,1,2,Premise,Premise,none,"The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.","Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017)."
16483488,1,3,Premise,Premise,none,"The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.","However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037)."
16483488,1,4,Premise,Premise,none,"The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.",There was no statistically difference between the two groups regarding quality of life.
16483488,1,5,Premise,Claim,support,"The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.","Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC."
16483488,2,1,Premise,Premise,none,"Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).","The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively."
16483488,2,3,Premise,Premise,none,"Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).","However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037)."
16483488,2,4,Premise,Premise,none,"Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).",There was no statistically difference between the two groups regarding quality of life.
16483488,2,5,Premise,Claim,support,"Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).","Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC."
16483488,3,1,Premise,Premise,none,"However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).","The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively."
16483488,3,2,Premise,Premise,none,"However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).","Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017)."
16483488,3,4,Premise,Premise,none,"However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).",There was no statistically difference between the two groups regarding quality of life.
16483488,3,5,Premise,Claim,support,"However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).","Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC."
16483488,4,1,Premise,Premise,none,There was no statistically difference between the two groups regarding quality of life.,"The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively."
16483488,4,2,Premise,Premise,none,There was no statistically difference between the two groups regarding quality of life.,"Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017)."
16483488,4,3,Premise,Premise,none,There was no statistically difference between the two groups regarding quality of life.,"However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037)."
16483488,4,5,Premise,Claim,support,There was no statistically difference between the two groups regarding quality of life.,"Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC."
16483488,5,1,Claim,Premise,none,"Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.","The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively."
16483488,5,2,Claim,Premise,none,"Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.","Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017)."
16483488,5,3,Claim,Premise,none,"Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.","However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037)."
16483488,5,4,Claim,Premise,none,"Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.",There was no statistically difference between the two groups regarding quality of life.
